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The ability of embryonic stem cells (ESCs) to self-renew and differentiate into a wide 
range of cell types has encouraged researchers to attempt to isolate ESCs from embryos 
of domestic species for the past two decades. Success has been limited. The aim of the 
current study was to investigate whether colonies derived from inner cell masses (ICMs) 
of bovine blastocysts expressed the same markers of pluripotency and candidate genes 
representing the various signaling pathways as those found in human or mouse ESCs. 
The ability of selected cytokines to maintain the major transcription factors associated 
with pluripotency (NANOG, POU5F1 and SOX2) in the ICM explants was also tested. 
The results of the study showed that the three major transcription factors (NANOG, 
POU5F1 and SOX2) were expressed initially in culture but were lost with continued 
culture and passaging. Markers of differentiation (BMP4, HNF4, NCAM, and CDX2) 
were also expressed in the initial days of culture. The candidate genes representing the 
various signaling pathways were expressed in the initial days of culture as well as in 
subsequent passages. Noggin, a cytokine inhibiting the BMP4 pathway successfully up-
regulated the relative expression of NANOG in the ICM explants with respect to controls. 
The results indicate that signaling pathways associated with regulating pluripotency are 
expressed in ICM explants and that with cytokine supplementation pluripotency may be 
maintained. An alternate approach in which differentiating cells in the primary colonies 
were selectively ablated to eradicate cells secreting pro-differentiation signals was tested. 
Bovine embryos that carried the hygromycin resistance gene driven by the NANOG 
promoter were generated by SCNT. Any pluripotent colonies generated from these 
embryos should survive in the presence of hygromycin. When cultured in the presence of 
Noggin and hygromycin, colonies were generated; however they failed to proliferate on 
passaging. This suggests that the culture conditions were not optimal for the NANOG 
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 Embryonic stem cells (ESCs) are characterized by their ability to self-renew 
and capacity to give rise to a broad spectrum of differentiated cell types. Pluripotency 
is maintained during ESC self-renewal through the promotion of proliferation and the 
prevention of differentiation. ESCs can proliferate for extended periods of time, be 
manipulated genetically using recombinant DNA technology, be directed for targeted 
differentiation and have a capacity for germline transmission. These qualities have 
made ESCs an excellent tool for genetic engineering (Capecchi 1989) by virtue of 
which they been used extensively in investigations of functional genomics. As a 
result, these successes have stimulated research interest for the derivation of ES and 
ES-like cell lines from livestock and other laboratory species. Despite many efforts to 
derive ESCs from other mammalian species, ESCs that retain their capacity for 
germline transmission have only been verified in the mouse.  
 Promising results with hESCs and adult stem cells have nurtured hope for 
their potential use in regenerative medicine. However, such an application is still far 
from reality since substantial research is required to elucidate the yet unknown 
aspects of the basic biology of pluripotent cells, as well as safety issues associated 
with their use in therapy. In this context, the derivation, propagation and 
differentiation of ESC-like cultures from domestic animals as biologically relevant 
models has gained interest. ES-like cells derived from livestock can also potentially 
be used for creating transgenic livestock. The practical aspects of these animals 
include improvement in milk production and composition, increase in growth rate, 
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improved feed usage, improved carcass composition, increased disease resistance, 
enhanced reproductive performance and increased prolificacy. In addition, ESCs and 
ES-like cells are also being viewed as a tool for the production of tissues and organs 
for xenotransplantation. Partcular interest has been focused on pigs genetically 
modified with the aim to overcome immune rejection by the human host (Wobus and 
Boheler, 2005). 
 However the principle interest for creating transgenic animals is the 
production of genetically modified animals to serve as bioreactors for commercially 
important proteins such as Anti-thrombin III, Factor IX, α-antitrypsin (Ebert et al., 
1991; Schnieke et al., 1997; Wright et al., 1991) to name a few. Despite the lower 
costs of producing biomolecules in microorganisms, like bacteria and yeast, these 
organisms do not properly execute several post-translational modifications, and 
correct folding in order to produce fully active human proteins (Melo et al., 2007). At 
the same time, the price of human biomolecules produced in vitro by mammalian cell 
culture is extremely high. This makes the creation of transgenic animals with the 
capability of secreting these products in their fluids potentially lucrative (Melo et al., 
2007). 
 Traditionally, transgenic livestock have been generated employing the 
procedures of pronuclear (PN) microinjection and somatic cell nuclear transfer 
(SCNT). PN microinjection allows addition of DNA fragments to the genome 
however they integrate randomly (Wolf et al., 2000). Schnieke et al. (1997) showed 
that SCNT was more efficient for the production of founder animals (sheep) as 
compared to DNA microinjection. However, primary somatic cells used for SCNT 
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procedures have a limited lifespan in vitro and clonal selection and transfection of 
these cells further compromise cell vigor and usability for this purpose (Denning and 
Priddle, 2003). Bovine fetal fibroblast cells, which are commonly used to make 
transgenic cattle, have 30–50 population doublings before senescence (Polejaeva and 
Campbell, 2000). Clarke and coworkers (2000) have estimated that gene targeting 
requires around 45 population doublings in sheep. ESCs and ES-like cells with their 
capability to proliferate for extended periods of time would alleviate this problem. 
 Successful production of chimeric cattle was achieved when ES-like cells 
were isolated from early embryos, transfected with exogenous DNA, reintroduced 
into pre-implantation embryos. The transgenic cells were shown to contribute to 
tissues of the resulting calves; however, these ES-like cells did not contribute to the 
germline of these chimeric animals (Cibelli et al., 1998). Furthermore, ES-like cells 
thus far obtained have been difficult to passage or grow clonally which would hinder 
use of sophisticated genetic manipulations. 
 Efficient procedures for production of in vitro embryos in cattle make bovine 
embryos an abundant source for the derivation of ESC-like procedures. While 
numerous studies have attempted to derive ES cells from bovine embryos (Milatipova 
et al., 2001; Strelchenko 1996; Stice et al., 1996; Cibelli et al., 1998; Iwasaki et al., 
2000; Saito et al., 2003; Wang et al., 2005), success has been limited. Whether the 
difficulties result from inadequate knowledge or inherent recalcitrance within the 
system is not known. The overall goal of this research was to investigate some of the 
factors which may be contributing to these hurdles. 
 The main objectives of this research were to determine whether; 
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1. Bovine embryos and explants express the same core of pluripotency 
determining factors as hESCs and mESCs, 
2. Bovine explants respond to the same cytokines as either hESCs and mESCs, 
and 
3. By selectively ablating differentiating cells, the proliferation and maintenance 
of pluripotent cells would be encouraged. 
It is hoped that the findings of this research will provide insights into the reason that 
makes derivation and maintenance of ES-like cells from bovine embryos difficult. At 
the same time it is anticipated to provide leads that will enable the derivation of ESCs 










Characteristics of Embryonic Stem Cells 
 There are three basic types of stem cells that exist in mammals: somatic, 
germinal and embryonal stem cells. Embryonic carcinomas (EC) cells were the first 
pluripotent cells isolated from teratocarcinomas; teratocarcinomas are complex 
tumors comprising of a mixture of germ cells and derivatives of all the three lineages: 
endoderm, mesoderm and ectoderm (Martin and Evans, 1975). As pluripotent cells, 
EC cells are capable of multilineage differentiation, but they have had limited 
applications due to frequent aneuploidy and restricted ability to colonize germ lines 
(Martin, 1980). Primordial germ cells (PGCs) are another pluripotent cell population. 
PGCs are isolated from the genital ridge of the post-implantation embryo (Shamblott 
et al., 2001; Resnick, 1992; Liu et al., 2004). Embryonic stem cells (ESCs) are 
pluripotent cells derived from pre-implantation embryos that are also capable of 
differentiating into all the three cell lineages as well as into germ cells. Murine ESCs 
were first derived by Evans and Kaufmann (1981) and Martin (1981) from the inner 
cell mass (ICM) of blastocysts and since then have also been derived from 
blastomeres of morulae (Tesar, 2005; Eistetter, 1989) and 8-cell embryos (Tesar, 
2005; Delhaise et al., 1996) and primitive ectoderm of implantation-delayed 
blastocysts (Prelle et al., 2002). 
 The derivation of ESC lines entails diversion of the pluripotent epiblast or 
blastomeres from their fated differentiation. Most murine ESC lines have been 
isolated from embryos of the inbred strain 129 and its various sub-strains. Most other 
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mouse strains have been refractory to isolation of ESCs indicating a strong genetic 
component to ESC derivation (Kawase et al., 1994). At the same time, though these 
cells have demonstrated competence to form all cell types within the fetus, a strong 
ES cell contribution to the entire fetus (including embryonic derived placental tissues) 
following chimera formation has not yet been demonstrated in either mice or non-
human primates. However, under certain limited conditions mouse ESCs can form 
trophectodermal cells in vitro (Ralston and Rossant, 2005) and in vivo (Beddington 
and Robertson, 1989), while human and other non-human primate ESCs can 
differentiate readily into trophectodermal cells (Thomson et al., 1995; Xu et al., 
2002). 
 ESC lines are capable of sustained self-renewal and wide-ranging 
differentiation plasticity. They can be propagated clonally as a homogenous, 
uncommitted cell line without losing their pluripotency or stable karyotype for 
prolonged periods of time. Murine ESCs are capable of integrating into the early 
developing embryo even after extensive genetic manipulation, with the ESC 
descendants being represented among all cell types, including functional gametes 
(Kehler et al., 2005). These properties make murine ESCs an important tool for 
genetic engineering especially via homologous recombination to make precise 
modifications to the germline (Boiani and Scholer, 2005). Human ESCs share all the 
same properties except for the fact that the germline capability cannot be tested due to 
ethical considerations (Pera et al., 2000). However, unless germline transmission is 
proven in the pluripotent cells derived from embryos of species other than primates, 
they are generally referred to as ES-like cells. These wide-ranging properties of ESCs 
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have made them an important instrument in the study of developmental biology. The 
broad ranges of applications of mouse and human ESCs have generated strong 
interest among scientists working with other species such as cattle and pigs. 
 
Creation of transgenic livestock 
 In farm animals, transgenic research is focused on production characteristics 
such as growth and body composition, lactation performance as well as disease 
resistance and immune resistance (Wheeler 2007). Transgenic farm animals have the 
potential to become important tools for biomedical research, either as disease models 
for production of therapeutic proteins, tissues or organs. Once available, ESCs from 
domestic species can potentially be used for the production of transgenic animals that 
will not only increase our understanding of basic developmental biology but also be 
important for biopharming. Production of transgenic livestock as ‘biopharms’ 
expressing proteins with potential therapeutic and commercial applications in their 
milk of livestock species was first demonstrated by Clark et al. in 1989. The most 
popular methods employed to generate transgenic animals is by the use of PN 
microinjection and somatic cell nuclear transfer (SCNT) technologies. 
 One of the techniques employed to generate a transgenic animals is pronuclear 
microinjection in which the DNA is inserted into the pronucleus of a fertilized oocyte. 
The success of pronuclear injection with respect to transgene integration ranges from 
around 1% for farm animal (cattle, pigs and sheep) to 3% for laboratory animals 
(mice, rats and rabbits) (Wall, 1996). This method usually results in mosaics in which 
not all cells of the animal contain the transgene. The time and cost of screening for 
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germline transmission in mosaic animals such as cattle can be substantial. Also there 
is a high variability in transgene expression between animals not only due to 
mosaicism but also to chromosomal position effects as a result of the random 
integration of the transgene. Microinjection is also limiting as it only allows for the 
random addition of exogenous DNA rather than targeting to specific sites (Hodges 
and Stice, 2003). 
 Somatic cell nuclear transfer (SCNT) is a technique that can be used to create 
a transgenic animal. It involves the transfer of a donor nucleus into the cytoplasm of 
an enucleated oocyte. Prior to SCNT, donor cells are transfected, propagated and 
tested for the incorporation of the transgene by molecular techniques. SCNT allows 
for not only the addition of DNA at random sites but also targeted insertion of DNA 
by homologous recombination which enables modulation of specific gene expression 
and creation of gene knockouts. The success rate for SCNT averages between 1-3% 
in most animals including cattle (Solter, 2000). A large number of transplanted 
embryos are lost during pregnancy and perinatal development. These neonatal losses 
are not due to any one anomaly but rather complications that can range from 
increased birth weight, pulmonary abnormalities, respiratory problems, to metabolic 
deficiencies and placental abnormalities (Hodges and Stice, 2003). 
 Other popular methods of generating transgenic mice include the use of viral 
vectors such as replication-defective retroviruses (Xia et al. 2007) and adenoviruses 
(Tsukui, 1996), which have a high efficiency of stable single copy integration. In 
addition, mammalian spermatozoa which have the ability to bind exogenous DNA 
molecules (Brackett et al. 1971) as well as internalize them have been used as carriers 
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of DNA, although the results of sperm-mediated gene transfer are controversial due to 
the low efficiency and repeatability (Gandolfi, 2000). 
 Ever since it was demonstrated that a targeted mutation could be introduced 
into ESCs by homologous recombination (Thomas and Capecchi, 1987) and germline 
transmission of a targeted mutation could be obtained allowing chimera production 
(Thompson et al., 1989), ESCs have become the most popular method for creating 
transgenic mice. Due to their rapid proliferation, ESCs provide an inexhaustible 
supply of cells for genetic manipulation. Individual transfected clones can be 
screened in vitro for integration and expression of exogenous DNA construct before 
creating germline chimeric animals (Wheeler et al., 1995), which increases the 
efficiency of producing transgenics. Numerous endogenous genes have been targeted 
by homologous recombination in pluripotent ESCs in culture (Ma et al., 2003; Pfiefer 
et al., 2002; Stanford et al., 2001). Unfortunately, despite intensive efforts, this 
technology is limited to the mouse as no germline competent ESCs have been 
described for any other mammalian species. 
  
Current status of embryonic stem cell research in domestic species 
 Efforts to derive ESCs from pig, goat, sheep and horse have most often been 
attempted with in vivo blastocysts. Peer-reviewed reports of porcine ES, ES-like or 
ICM cell lines have been published, using in vivo-derived (Notarianni et al., 1990, 
1991; Piedrahita et al., 1990; Hochereau-de Reviers and Perreau, 1993; Wheeler, 
1994; Chen et al., 1999; Li et al., 2003, 2004), as well as, in vitro produced (IVP) 
embryos (Li et al., 2004). Most attempts at deriving ESCs from bovine pre-
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implantation embryos has involved in vitro-produced embryos that have lesser 
developmental competence than in vivo derived embryos (Bavister, 2004). 
Production of ovine (Notarianni et al., 1991; Zhua et al., 2007), equine (Saito et al., 
2002) and caprine ES-like cell lines has also been reported (Keefer et al., 1996). 
However, the few attempts with in vivo derived embryos from bovine and other 
species have not had any more success. Similarly, a few ES-like cell lines from 
rodents other than the mouse (hamster, Doetschman et al., 1988; rat, Iannaccone et 
al., 1994; Vassilieva et al., 2000) and from rabbit (Schoonjans et al., 1996) have been 
reported. At the same time, there are several reports of embryonic germ (EG) cell 
lines derived from pig, goat and bovine PGCs derived from primordial germ cells 
found in the early genital ridge tissue, (Piedrahita et al., 1997; Shim et al., 1997; 
Mueller et al., 1999; Tsung et al., 2003; Rui et al., 2004). 
 Establishment of ESCs from ungulate embryos including bovine has been 
problematic. There are several published reports of bovine ES or ES-like cell lines 
from IVP early blastocyst-staged embryos (Saito et al., 2002, 2003; Sims and First, 
1994; Cibelli et al., 1998; Iwasaki et al., 2000; Mitalipova et al., 2001; Wang et al., 
2005).  Some of these bovine ES-like cell lines have been reported to exhibit 
pluripotency both in vitro and in vivo. However, teratoma formation in 
immunocompromised mice has rarely been reported for putative ungulate ESC lines, 
with a few exceptions (Hochereau-de Reviers and Perreau 1993; Anderson et al. 
1996). While ES-like cells can be used in SCNT to create cloned animals (Keefer et 
al., 1994; Stice et al, 1996; Chen et al., 1999; Saito et al., 2003), few of the putative 
ES-like cells morphologically resemble mESCs or express markers that are normally 
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associated with ESC lines (Mitalipova et al., 2001; Stice et al., 1996; Cibelli et al., 
1998; Saito et al., 2003). For instance, POU5F1 is found to be associated with the 
pluripotency of ES-like cells in many species, however, few of the previously 
reported bovine ES-like cell lines were POU5F1 positive (Mitalipova et al., 2001; 
Stice et al., 1996; Cibelli et al., 1998; Saito et al., 2003) except for one report by 
Wang et al. (2005) where they found NT derived ES-like cell lines positive for 
POU5F1. However, no such results were reported for IVP bovine embryos in that 
study. Furthermore, POU5F1 protein is expressed in both the ICM and trophectoderm 
of ungulates, i.e., pigs, cattle and goats (van Eijk et al., 1999; Kirchhof et al., 2000; 
He et al., 2004). Cell surface markers, SSEA1 and SSEA4 have been shown in ICM 
and trophectoderm of caprine embryos (He et al., 2006) and in ICM cultures of NT 
embryos (Wang et al., 2005). NANOG, a key marker of pluripotency is found in the 
ICM caprine blastocysts (He et al., 2006) but there are no such published reports for 
expression of NANOG protein in bovine embryos. 
 ESCs are commonly derived from preimplantation embryos by placing a 
hatched blastocyst or zona-free pre-blastocyst stage embryos on a feeder layer and 
thereafter sub-culturing the ES-like cells. Another method employed for isolation of 
the ICM from the blastocyst is immunodissection, where the trophectoderm of the 
blastocyst is targeted and destroyed using antibodies. Immunodissection is the 
preferred method for derivation of hESC (Trounson 2006; Pera et al., 2000) where 
persistence of trophectoderm is a problem whereas whole embryo culture is usually 
employed for derivation of mESC (Bryja et al., 2006). Murine ESCs are propagated 
by enzymatically dissociating colonies and plating individual cells for new colony 
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formation (Thomson et al., 1998; Evans and Kaufmann, 1981). Human ESCs are also 
routinely passaged by enzymatically dispersing the cells with dispase or collagenase 
(Yao et al., 2006). However, bovine ES-like cells fail to form colonies after 
enzymatic disassociation with trypsin, collagenase, protease etc. (Mitalipova et al., 
2001; Cibelli et al., 1998; Wang et al., 2005). Trypsin is the only reported enzyme 
that dissociates bovine ES-like cells, but it also causes a failure of these cells to self-
renew and to induce spontaneous differentiation (Wang et al., 2005). This 
refractoriness of ES-like cells to enzymatic dissociation has made it difficult to pursue 
a clonal propagation of most ES-like cells derived from domestic species including 
bovine ES-like cells.  
 
Signaling pathways and transcription factors in stem cell biology 
Transcription factors: major players 
POU5F1 (Oct3/4 or Oct4) 
POU5F1 is encoded by the POUF51 gene and is a member of the POU (Pit-Oct-Unc) 
transcription factors. In mESCs DNA binding is mediated by the 75-amino acid POU-
specific domain (POUS) and the 60-amino acid carboxy-terminal POU homeodomain 
(POUHD). POU5F1 binds to the octamer motif ATGCAAAT. A proximal enhancer 
(located about 1.2 kb upstream) is responsible for POU5F1 expression in the epiblast, 
and a distal enhancer region (located about 2 kb upstream) drives expression in the 
morula, ICM, and primordial germ cells. This distal enhancer is also required for 
ESC-specific expression (Yeom et al., 1996). Orthologs of POU5F1 share a high 
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degree of genomic structural organization and sequence conservation across other 
mammalian species including bovine, human and mouse (van Eijk et al., 1999).  
 Prior to zygotic gene activation, maternally derived POU5F1 mRNA can be 
detected in the ovum through the four cell stage in mouse and 8 cell stage in bovine 
embryos (Kurosaka et al., 2004). During mouse pre-implantation development, 
POU5F1 zygotic expression is initiated at the four-cell stage and is later restricted to 
the pluripotent ICM cells of blastocysts and, thereafter, to the epiblast and finally to 
the germ cell lineage (Boiani et al., 2002; Yeom et al., 1996).  
 POU5F1 is expressed also in human and mouse ESCs, and its expression 
diminishes when these cells differentiate and lose pluripotency (Ginis et al., 2004). A 
knockdown of POU5F1 expression in mESCs correlates with induction of 
trophectoderm genes CDX2, HAND1, and PL-1, with formation of cells with 
trophoblast giant cell phenotype. Contrarily reduction of its expression leads to 
expression of endodermal markers such as Gata6 in both mES and hESCs (Hay et al., 
2004). Maintaining POU5F1 expression within a certain range appears to be critical 
for mESC renewal, with an increase or decrease beyond the threshold of 50% 
triggering differentiation to endoderm and mesoderm or to trophectoderm, 
respectively (Niwa et al., 2000). However, POU5F1 expression alone is not sufficient 
to maintain the undifferentiated phenotype and requires a co-operative signal 
provided by LIF stimulation in mESCs.  
 Numerous target genes of POU5F1 in ESCs have been identified, and these 
include FGF4, UTF1, OPN, REX1/ZFP42, FBX15, and SOX2 (Chew et al., 2005; 
Table 1A). The POU octamer elements within the enhancers of the above mentioned 
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genes are found in proximity to SOX2-binding elements. Both POU5F1 and SOX2 
are expressed in ESCs and are capable of forming heterodimers both on and off the 
DNA. A composite SOX2-POU5F1 cis-regulatory site on the NANOG promoter and 
has been determined to be necessary for pluripotent expression and both SOX2 and 
POU5F1 have been shown to bind this module both in vitro and in mouse and human 
ESCs (Kuroda et al. 2005; Rodda et al., 2005; Okumura-Nakanishi et al., 2004). 
POU5F1 and SOX2 regulate the expression of NANOG, and POU5F1 is required for 
the efficient binding of SOX2 to the NANOG promoter (Rodda et al., 2005; Kuroda 
et al., 2005; Figure 1). These three transcription factors, NANOG, POU5F1 and 
SOX2 work in concert to regulate expression of genes in pluripotent cells and a 
substantial proportion of the POU5F1-bound genes (44.5%) have been demonstrated 
to be occupied by both NANOG and POU5F1 (Loh et al., 2006). 
 
SOX2 (SRY-related HMG box 2) 
SOX2 is a transcription factor belonging to the SRY-related HMG (high mobility 
group) box containing gene family and is a transcription factor essential for 
pluripotent cell development (Avilion et al., 2003). It has an expression pattern 
similar to that of POU5F1 during mouse pre-implantation development, as it is 
expressed in all blastomeres of the four-cell embryo and becomes restricted to the 
ICM and epiblast of the blastocyst (Avilion et al., 2003). SOX2 is required to 
maintain cells of the epiblast in an undifferentiated state, and in its absence they 
change their identity, becoming trophectoderm or extra-embryonic endoderm (Avilion 
et al., 2003). SOX2-null cells differentiated into trophoectoderm-like cells (Masui et 
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al., 2007; Figure 2). Two regulatory regions (SRR1 and SRR2) in SOX2 are known to 
confer ESC-specific expression (Tomioki et al., 2002). SRR2, located 1.2 kb 
downstream of the transcription start site, contains the composite POU5F1-SOX2 
element. It acts synergistically with POU5F1 and silencing of POU5F1 or SOX2 
leads to the down-regulation of POU5F1 and SOX2 enhancer activities and reduction 
in the endogenous transcripts and proteins (Chew et al., 2005). However, involvement 
of multiple Sox factors such as Sox4, Sox11 or Sox15 in activation of SOX2-
POU5F1 enhancers in ESCs has shown that SOX2 function can be redundant (Masui 
et al., 2007) and they can functionally replace Sox2. However, SOX2 is necessary for 
regulating multiple transcription factors that affect POU5F1 expression and forced 
expression of POU5F1 rescues the pluripotency of SOX2-null ESCs. These results 
indicate that the essential function of SOX2 is to stabilize ESCs in a pluripotent state 
by maintaining the requisite level of POU5F1 expression. On the other hand, Boer et 
al. (2007) demonstrated that elevating SOX2 levels inhibits the endogenous 
expression of five SOX2:POU5F1 target genes (SOX2, FGF-4, NANOG, UTF1 and 
POU5F1 ) that are regulated by closely spaced HMG and POU motifs (referred to as 
an HMG/POU cassette), which bind SOX2 and POU5F1, respectively (Table 1B). In 
addition, SOX2 repression is dependent on the binding sites for SOX2 and POU5F1. 
Although over-expression of POU5F1 and NANOG also inhibits their own promoter, 
their over-expression does not appear to broadly inhibit the promoters of other 






 NANOG is a divergent NK2 homedomain (HD) transcriptional factor that 
functions to maintain self-renewal of embryonic stem (ES) cells (Mitsui et al., 2003; 
Chambers et al., 2003). In mouse embryos, NANOG mRNA is detectable as early as 
the morula stage. Its expression is prominent in the inner cell mass of the blastocyst 
(Palmieri et al., 1994; Avilion et al., 2003). After implantation, it is detectable at 
embryonic day 6 in the proximal epiblast in the region of the presumptive streak and, 
thereafter, in the pluripotent cells of the nascent gonad at E11.5-E12.5 (Hart et al., 
2004). NANOG expression is restricted to pluripotent tissues, ESC lines and human 
germ cell tumors (Hart et al., 2005) and is dramatically reduced by retinoic acid-
induced differentiation. NANOG over-expression in hESCs enables their propagation 
for multiple passages during which the cells remain pluripotent (Darr et al., 2006; 
Chambers et al., 2003). Its over-expression in mESCs renders them independent of 
LIF supplementation (Chambers et al., 2003; Mitsui et al., 2003) as well as resistant 
to differentiation by retinoic acid (Loh et al., 2006). Reduction in NANOG expression 
correlates with induction of extraembryonic endoderm genes GATA4, GATA6, and 
laminin B1, with subsequent generation of groups of cells with parietal endoderm 
phenotype (Hough et al., 2006; Figure 2). A similar cell type is formed upon ectopic 
GATA6 expression in mESCs (Fujikura et al., 2002) raising the possibility that 
NANOG may prevent primitive endoderm differentiation via GATA6 repression. Lin 
et al. (2004) reported that tumor suppressor p53 promoted differentiation of ESCs by 
suppressing NANOG expression. The p53 protein can also bind to the NANOG 
promoter after DNA damage to ESCs resulting in suppression of NANOG expression 
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and triggering differentiation to maintain genomic stability. NANOG over-expression 
has also been shown to cause proliferation of NIH3T3 cell by promoting them to 
enter into S phase (Zang et al., 2006).  
 The NANOG promoter region has two transcription start sites and has binding 
sites for POU5F1 (Wu et al., 2005). Analysis of mouse and human NANOG revealed 
that the C-terminal domain is responsible for trans-activation (Pan et al., 2005; Oh et 
al., 2005). Although NANOG and POU5F1 have discrete functions in self-renewing 
ESCs, NANOG cannot function in the absence of POU5F1, suggesting 
interdependent modes of action (Chambers et al., 2003).  
 Although NANOG has been shown to be positively regulated by POU5F1 and 
SOX2, there is evidence that they are not the only players involved in its regulation 
(Chambers et al., 2003). It was found that greater than 90% of promoter regions of 
various genes that are bound by both POU5F1 and SOX2 are also occupied by 
NANOG and their binding sites are in close proximity to each other. Together they 
co-occupy the promoter regions of transcription factors (eg. POU5F1, SOX2, 
NANOG, STAT3, etc.), members of the TGF-β and WNT signaling pathways, genes 
involved in differentiation into various lineages, and genes encoding components of 
chromatin remodeling and histone-modifying complexes (Boyer et al., 2005). Loh et 
al. (2005) proposed that NANOG sustains self-renewal and the undifferentiated state 
through the modulation of POU5F1 and SOX2 levels (Figure 1). These two 
transcription factors in turn control the downstream genes important for maintaining 
pluripotency or inhibiting differentiation. In addition, NANOG also controls 
important molecular effectors of ESC fate by regulating genes transcribing histone 
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methyltransferases, telomeric proteins and those responsible for transcriptional 





Figure 2: Role of transcription factors in maintenance of pluripotency. 
NANOG, POU5F1 and SOX2 function by preventing the pluripotent cell from 
differentiating into specific lineages and thereby maintain self-renewal of 
ESCs. 
Figure 1: Transcriptional regulated circuitry in ESCs. The transcription factors 
Nanog and the dimerized form of Pou5f1 and Sox2 regulate the transcription of 

















Figure 2: Role f transcription factors in maintenance of pluripotency. NANOG, 
POU5F1 and S X2 function by preventing the pluripoten  cell from 
differentiating to specific lineag s and, thereby, maintaining self-renewal of 
ESCs. 
Figure 1: Transcriptionally regulated circuitry in ESCs. The transcription factors 
NA OG and the dimerized form of POU F   OX2 regulate the transcription 
of their ow  genes as well of oth r genes expressed in ESCs. Adapted from Boyer 
et al., 2005. The solid arrows indicate the genes regulated by the Pou5f1:Sox2 





Genes Function Reference 
FGF4 Early embryonic development Dailey et al., 1994 
UTF1 Transcription co-activator/repressor, 
chromatin associated 
Nishimoto et al., 1999; van 
den Boom et al., 2007 
OPN Negatively regulates the pool size of 
hemapoetic stem cells in bone marrow 
Botquin et al., 1998 
REX1 Zinc-finger protein Rosjford et al., 1994 
FBX15 Phosphorylation-dependent ubiquitination Tokuzawa et al., 2003 
SOX2 Transcription activator, maintains 
pluripotency 
Catena et al., 2004 
FGFR4 Early embryonic development McDonald and Heath, 
1994 
FOXD3 Trophoblast progenitor cell differentiation 
 







Genes Function Reference 
NANOG Transcription activator, maintains 
pluripotency 
Rodda et al., 2004 
UTF1 Transcription co-activator/repressor, 
chromatin associated 
Nishimoto et al., 1999;  
OPN Negatively regulates the pool size of 
hemapoetic stem cells in bone marrow 
Botquin et al., 1998 
SOX2 Transcription activator, maintains 
pluripotency 
Tomioka et al., 2002 
FGF4 Early embryonic development Yuan et al., 1995 
POU5F1 Transcription activator, maintains 
pluripotency 
Chew et al., 2005 
 
Table 1B: Genes regulated by POU5F1:SOX2 dimer 
Table 1 A: Genes regulated by POU5F1 
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Transcription factors: minor players 
 REX1: REX1 is a developmentally regulated acidic zinc finger protein gene 
(ZFP-42).  REX1 mRNA is detected in a limited range of cells and tissues: 
undifferentiated ESCs and EC cells, mouse blastocysts including trophectoderm, and 
meiotic germ cells of the adult mouse testis (Rogers et al., 1991). . Knockdown of 
NANOG in embryonic stem cells results in a reduction of REX1 expression. 
NANOG, POU5F1 and SOX2 can transactivate REX1 promoter (Ben-Shushan et al., 
1998; Shi et al., 2006). Though REX1 has been shown to be regulated by 
pluripotency related transcription factors, it has not yet been demonstrated to 
influence transcriptional factor networks or signaling pathways in ESCs. 
 
 SALL4: SALL4 is a member of spalt-like protein family. It is a zinc finger 
protein thought to act as a transcription factor. It is downstream of the WNT pathway 
and is regulated by TCF/LEF1 (Bohm et al., 2007). It is also known to be expressed 
predominantly in the ICM of early mouse embryos (Yoshikawa et al., 2006), in 
embryonic carcinoma cells and in the adult testis and ovary. Disruption of both alleles 
of SALL4 leads to embryonic lethality during peri-implantation stage (Kohlhase et 
al., 2002). Wu et al. (2006) showed that SALL4 null-ESCs also have reduced 
proliferation in vitro. Furthermore, SALL4 bound to NANOG, POU5F1 and SOX2 
upstream regulatory sequences. These early results show that SALL4 is involved in 





 FOXD3: FOXD3, a member of the forkhead family of transcriptional 
regulators, is required for maintenance of embryonic cells of the early mouse embryo. 
FOXD3 expression is detected during early embryogenesis in the epiblast and later in 
neural crest cells (Dottori et al. 2001). It has been implicated in the control of 
differentiation in multiple systems (Hanna et al., 2002). FOXD3 null embryos die 
after implantation at approximately 6.5 days postcoitum with a loss of epiblast cells. 
Moreover, it has not been possible to establish FOXD3 null ESC lines or to generate 
FOXD3 null teratocarcinomas (Hanna et al., 2002).  
 
Factors and inducers of pluripotency 
 Recent studies have further investigated the induction and maintenance of 
pluripotency by attempting to induce pluripotency in differentiated mouse fetal and 
adult cells by introducing four selected transcription factors, POU5F1, SOX2, c-MYC 
and KLF-4 (Takahashi et al., 2006; Okita). The authors started with a panel of 24 
transcription factors and narrowed it down to the above mentioned four factors based 
on the ability of the transcription factors to maintain pluripotency. The retroviral 
introduction of these factors transformed the cells into an ES-like state in terms of 
morphology, proliferation and teratoma formation (Takahashi et al., 2006). Using 
improved selection strategies it was possible to obtain germline-competent iPS cells 
(induced pluripotent cells) which exhibited increased ESC-like gene expression and 
DNA methylation patterns (Okita et al., 2007; Meissner et al., 2007). Another study 
by Yu et al. (2007) with a similar set of transcription factors (OCT4, SOX2, NANOG, 
and LIN28) showed that introduction of these factors is sufficient to reprogram 
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human somatic cells to pluripotent stem cells to exhibit the essential characteristics of 






LIF-Jak STAT Pathway 
 Mouse ESCs have historically been maintained in a co-culture with 
mitotically inactivated mice fibroblast (Evans and Kaufmann, 1981; Martin, 1981). 
Supplementation with LIF (leukemia inhibitory factor) eliminated the need for the co-
culture system (Smith et al., 1988). LIF signaling is largely, though not wholly 
responsible for maintenance of pluripotency in mESCs. LIF is a member of the LIF-
oncostatinM-Il-6 superfamily of cytokines. It acts by engaging a heterodimeric cell 
surface receptor complex comprising the LIF receptor subunit (LIFR; Gearing et al., 
1992) and glycoprotein 130 (GP130; Davis et al., 1993). A family of related 
cytokines, including cardiotrophin 1, oncostatin M and ciliary neurotrophic factor, 
that interact with the LIFR/GP130 complex can substitute for LIF and support ESC 
self-renewal (Boiani and Scholer, 2005).  
 Dani et al., (1998) demonstrated that embryos lacking LIFR or GP130 can 
develop beyond gastrulation, which suggests the existence of an alternative 
pathway(s) governing the maintenance of pluripotency in vivo. They generated 
mESCs in which both copies of the LIF gene were deleted. Though these cells 
showed a significantly reduced capacity for regeneration of stem cell colonies, self-
renewal was not abolished and undifferentiated ESC colonies were still obtained in 
the complete absence of LIF. LIF-/- embryos can survive beyond implantation in a 
normal uterus; however LIF-/- females fail to support embryo implantation (Dani et 
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al., 1998). In the absence of maternal LIF, blastocysts fail to implant and enter a stage 
similar to that seen during delayed implantation (Stewart et al., 1994). 
 LIF binding to a LIFR induces LIFR-GP130 heterodimerization which results 
in the activation of receptor-associated kinases of the Janus family (Jak). Activated 
Jaks phosphorylate specific tyrosines on GP130 signaling complex creating docking 
sites for proteins on the activated receptor complex (Matsuda et al., 1994). When 
GP130 is phosphorylated, several signaling pathways are activated involving STAT 1 
and 3 including the extracellular signal receptor kinases (ERK1 and 2) and the 
phosphatidylinositol-3 kinases (PI-3K) (Figure 3; Cavaleri and Scholer, 2003). In 
addition, LIF induces SOCS (suppressor of cytokine signaling) proteins which are 
negative feed-back inhibitors. The transcription of SOCS inhibits the tyrosine 
phosphorylation of GP130 and STAT3 (Heinrich et al., 1998).   
 The stimulation of Ras/Raf/MEK/ERK signaling pathway by LIF leads to 
differentiation of mESCs (Figure 3; Burdon et al., 1999). Interference with this 
pathway by mutation of Grb2 or Shp2, inhibition of the activation of MEKs with the 
inhibitors PD98059 and UO126, or by dephosphorylating ERKs by mitogen activated 
protein kinase phosphatase 3 (MKP-3), promotes self-renewal by limiting 
differentiation (Burdon et al., 1999).  
 In absence of LIF signaling, induced either by LIF withdrawal or by the 
expression of a dominant interfering form of STAT3, mESCs differentiate into a 
morphologically mixed population of endoderm and mesoderm (Niwa et al., 1998). 
Constitutive activation of STAT3 in mESCs eliminates the requirement of LIF in 
mESC for maintenance of pluripotency (Matsuda et al., 1999). The inhibition of the 
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MEK/ERK pathway enhances the propagation of mESCs (Burdon et al., 1999) and 
facilitates the isolation of ESCs from normally refractory murine CBA blastocysts 
(Lodge et al., 2005). 
 Human ESCs express LIF, IL-6, and GP130 receptors, as well as the 
downstream signaling molecules. Although stimulation of hESCs with GP130 
cytokines results in a robust phosphorylation of downstream ERK1, ERK2, and Akt 
kinases, as well as the STAT3 transcription factor, the activation of STAT3 is 
insufficient to maintain hESCs an undifferentiated state. Continuous receptor or 
STAT3 activation is not sufficient to block hESC differentiation (Humphrey et al., 
2004; Daheron et al., 2004) demonstrating that this pathway is not sufficient for 
maintenance of pluripotency in hESCs.  
 Bovine LIF (bLIF) has been cloned and used in culture (Yamanaka et al., 
1999, 2001), but there is no commercially available bLIF. Therefore, most 
researchers have used human LIF (hLIF) to supplement the culture medium for 
bovine embryos and colonies derived from them because of its greater sequence 
homology compared to murine LIF (mLIF). While supplementation of embryo 
culture media with bLIF has been described to increase TE cell counts without 
affecting the ICM (Yamanaka et al., 1999, 2001), hLIF has been noted to increase 
(Sirisathien et al., 2003; Funston et al., 1997), decrease (Vejlsted et al., 2005) or have 
no effect on the ICM (Rodrigues et al., 2006) of the bovine blastocyst. At the same 
time, bovine ES-like cells have been derived in the presence hLIF (Saito et al., 2003) 
and the absence of exogenous LIF (Mitalipova et al., 2001). Furthermore, the 
generation of cell colonies from blastomeres has been demonstrated to not be 
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influenced by exogenous hLIF (Vejlsted et al., 2005; Rexroad et al., 1997). Based on 
the puslished results, it appears that bovine pluripotent cells resemble hESCs in terms 
of their response to LIF and that LIF does not seem to play a role in the maintenance 
















Figure 3: LIF regulated pathway in mESC. LIF binds to LIFR and GP130 
bringing the Janus kinases in proximity allowing them to phosphorylate each 
other, thereby further facilitating the recruitment and phosphorylation of STATs. 
The activated STATs dimerize and translocate to the nucleus where they cause 
transcription of other genes. Binding of LIF to these receptors also stimulates the 
MEK/ERK pathway that leads to differentiation. Inhibition of this pathway 























TGF-β (Transforming Growth Factor) Superfamily 
 The TGF-β superfamily has been shown to play an important role in the 
maintenance of pluripotency in mESCs and hESCs. The TGF-β superfamily exhibit 
two distinct modes of the ligand-receptor interaction: one exemplified by members of 
the BMP subfamily and the other represented by TGF-βs and Activins. BMP ligands 
such as BMP2 and BMP4 exhibit a high affinity for the extracellular ligand binding 
domains of the type I BMP receptors. The preassembled type I receptor-ligand 
complex binds the type II receptor (Shi and Massague, 2003). In contrast to the 
BMPs, TGF-β and Activin bind tightly to the type II receptor allowing the subsequent 
incorporation of the type I receptor, forming a large ligand-receptor complex 
involving a ligand dimer and four receptor molecules. Binding of the dimeric ligand 
to both receptors facilitates the phosphorylation and subsequent activation 
(phosphorylation of multiple serine and threonine residues in the GS region) of the 
type I receptor by the type II receptor kinases (Shi and Massague, 2003).  
 The intracellular messengers downstream from the activated receptors are the 
Smad proteins which can be divided into three classes: (1) receptor-mediated Smads 
(R-Smads; Smad 1, 5 and 8) that are phosphorylated in a ligand-specific manner by 
activated receptor complexes, (2) the common mediator Smad (co-Smad; Smad 4), 
and (3) the inhibitory Smads (I-Smads; Smad 6 and 7) that negatively regulate the 
Smad signal transduction pathway. The R-Smads on phosphorlyation form a complex 
with Smad 4 and the complex translocates to the nucleus where it can bind directly, or 
through transcriptional partners, to specific sequences in the promoters of target genes 
to regulate transcription (Varga and Wrana, 2005; Figure 4). 
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 Among the three classes of Smads, only R-Smads are directly phosphorylated 
and activated by the type I receptor kinases. Smad2 and Smad3 respond to signaling 
by the TGF-β subfamily (which includes TGF-β, Activin, nodal etc.) and Smads 1, 5, 
and 8 primarily to signaling by the BMP subfamily (which includes BMP 2/4). In the 
basal state, R-Smads are predominantly localized in the cytoplasm, whereas the I-
Smads tend to be nuclear. Smad4 is distributed in both the cytoplasm and the nucleus. 
After receptor activation, the phosphorylated R-Smads are translocated into the 
nucleus (Figure 4). Dephosphorylation by phosphatases as well as ubiquitination by 
ubiquitin ligases, leads to the termination of Smad signaling (Shi and Massague, 
2003). 
 The access of TGF-β ligands to their receptors is restricted by a diverse group 
of soluble proteins that act as ligand binding traps, sequestering the ligand and barring 
its access to membrane receptors. Noggin is employed to inhibit the BMP4 induced 
signaling cascade. It mediates its effect by competively binding to BMP receptors 
thereby obstructing BMPs to bind to them. 
 BMP4 has been shown to act synergistically with LIF and prolonged the self-
renewal of mESCs in serum-free medium (Ying et al., 2003).The requirement of 
serum during clonal expansion and de novo derivation of mESCs and has been shown 
to be replaceable by BMP4 (Ying et al., 2003). However, the effect of BMP4 on self-
renewal is dependant on the presence of LIF. In its absence, BMP4 is a strong inducer 
of mesodermal differentiation. In contrast, without BMP4, neural differentiation 
ensues; hence it appears that BMP4 blocks neural differentiation. BMP2/4 stimulates 
the transcription of Id (inhibitor of differentiation) genes (Hollanagel et al., 1999; 
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Ying et al., 2003) and constitutive expression of Id1 circumvents the requirement for 
BMP4 (Ying et al., 2003). Id family members encode negative regulators of the basic 
helix-loop-helix (bHLH) transcription factors. They are negative regulators of 
differentiation and positive regulators of proliferation (Hollanagel et al., 1999). 
Transient inhibition of BMP4 signaling by Noggin has been shown to induce 
cardiomyocyte differentiation of mouse embryonic stem cells (Yuasa et al., 2005). 
BMPs further support self-renewal of mESCs by inhibiting MAPK pathways (Qi et 
al., 2004) in mESCs. Specific inhibition of ERK or p38 kinases using 
pharmacological agents in mESCs dramatically improves self-renewal (Qi et al., 
2004). Pharmacological inhibition of Smad 2/3 encourages maintenance of 
pluripotency in ICM of mouse blastocysts outgrowths but not the maintenance of the 
undifferentiated state in mESCs (James et al., 2003).  
 Studies with hESCs suggest that BMPs promote differentiation which 
contrasts with their role in mESCs (Pera et al., 2004). Treatment with exogeneous 
BMP4 antagonist, Noggin prevents spontaneous differentiation into primitive 
endoderm. Noggin has been used to block the effects of BMP4 in order to derive 
neural cells (Pera et al., 2004; Lim et al., 2000). hESCs cultured in serum-free  
unconditioned medium (UM) are subjected to high levels of intrinsic BMP4 signaling 
activity, which is reduced in conditioned media (CM; media containing MEF secreted 
factors). hESCs cultured in the absence of feeders in CM supplemented with basic 
fibroblast growth factor (bFGF) and BMP4 tend to differentiate to trophoblast lineage 
(Xu et al., 2002). Replacing BMP4 with Noggin, Nodal or Activin A sustains 
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undifferentiated proliferation of hESCs in the absence of fibroblasts or CM (Xu et al., 
2005; Wang et al., 2005).  
 During early embryonic development, Nodal/Activin signals establish the 
embryonic axes, induce mesoderm and endoderm, pattern the nervous system, and 
determine left-right asymmetry in vertebrates (Schier, 2006). Nodal and Activin A 
bind activin receptors and activate Smad2 by phosphorylation. Activin A has been 
implicated in differentiation of mESCs into mesoderm, differentiation of human 
pancreatic precursor cells into beta cells, inhibition of neural differentiation and 
induction of hESCs into endoderm (Beattie et al., 2005). In undifferentiated hESCs 
maintained with CM, the TGF-β/Activin/nodal branch acts through Smad 2/3 
mediated signaling. On differentiation of hESCs, Smad 2/3 signaling is decreased 
while Smad 1/5 is increased (James et al., 2003). hESCs cultured in feeder-free 
conditions in the absence of CM can be maintained in an undifferentiated state upon 
supplementation with Activin A (Xiao et al., 2006; Levenstein et al., 2006; Beattie et 
al., 2005; Vallier et al., 2005). On withdrawal of Activin A or addition of the Activin 
inhibitor, follistatin, the cells differentiate (Beattie et al., 2005). Nodal also binds to 
Activin receptors and acts via the Smad 2/3 signaling pathway. Blocking of this 
pathway using a pharmacological inhibitor induces differentiation of hESCs which 
















































Figure 4: TGF-β signaling network in ESCs. The respective ligands bind to their 
respective Type I and Type II receptors. This ligand binding activates the receptors 
and they further phosphorylate and activate the respective Smads. The activated R-
Smads bind to Smad4 and are translocated to the nucleus where they facilitate the 
transcription of various ESC related genes. The ActRIIA receptors are represented 
in dark grey, ActRIIB in light grey and BMPRI and TGFRII in white. Smad 1/5/8 
represented in dark grey respond to activation by BMPs, Smad 2/3 represented in 
white respond to activation by the TGF branch, and Smad 4 acts as a cofactor to 
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FGF2 (Fibroblast Growth Factor 2) 
FGFs mediate cellular responses by binding to and activating the receptor tyrosine 
kinases (RTKs), FGF-receptors. FGF-stimulation leads to tyrosine phosphorylation of 
the docking protein FRS2a and FRS2b, followed by recruitment of multiple Grb2/Sos 
complexes resulting in activation of the Ras/MAP kinase, PLC-γ, and PI3K signaling 
pathways (Eswarakumar et al., 2006; Figure 5). FGFR signaling plays critical roles at 
different stages of embryonic development (Ornitz et al., 2001). FGF2, also known as 
basic FGF, has an octamer-containing enhancer downstream of the coding region 
which is activated synergistically by POU5F1 and SOX2.  FGF2 has been proposed 
to facilitate chromatin remodeling by suppressing methylation of histone 3 (H3) at 
STAT binding site (Song and Ghosh, 2004). The long-term culture and maintenance 
of human ESCs in the presence of serum does not require the addition of exogenous 
FGF2, however, in serum-free medium; FGF2 increases the initial cloning efficiency 
of human ESCs and FGF2 and is required for continued undifferentiated proliferation 
(Amit et al., 2000). When culturing hESCs in absence of feeders and without CM or 
serum, supplementation with FGF2 along with other growth factors like Noggin and 
Activin A, enhances the proliferation of pluripotent cells (Wang et al., 2005; Vallier 















Figure 5: FGF mediated signaling network. Binding of FGF to FGFR results in 
activation of the Ras/MAP kinase, PLC-γ, and PI3K signaling pathways. Adapted 




 The key cytoplasmic events in the canonical WNT pathway include inhibition 
of GSK-3β (glycogen synthase kinase 3β) mediated β-catenin degradation and 
selective β-catenin stabilization, nuclear localization and subsequent transactivation. 
Though the WNT proteins were first discovered as oncogenes in the mouse, they 
were later determined to perform important roles in axis formation and patterning in 
the developing embryo (Wang and Wynshaw-Boris, 2004). WNT ligands have been 
shown to promote proliferation and inhibit differentiation via different mechanisms in 
different stem cell and progenitor populations.  
 According to the most widely accepted canonical model of the β -catenin 
pathway, in the absence of WNT ligand, β -catenin is ubiquitinated, resulting in its 
degradation by the proteasome thereby reducing its cytoplasmic level. When WNT 
acts on the cell surface, free β-catenin accumulates and is translocated to the nucleus, 
where it binds to the promoter of its downstream target genes (Wang and Wynshaw-
Boris, 2004). β-catenin displaces transcriptional co-repressors and recruits 
transcriptional activators (Kikuchi et al, 2006; Figure 6).  
 The WNT ligands act on mESCs via the canonical pathway. Direct activation 
of β-catenin fully recapitulates the effect of WNTs on ESCs (Hao et al., 2006; Ogawa 
et al. 2006). WNTs and LIF have synergistic effects in the regulation of the activity of 
STAT3. WNT increases STAT3 mRNA, while the LIF promotes the phosphorylation 
of STAT3 proteins (Hao et al., 2006). Takao et al. (2007) demonstrated a decrease in 
β-catenin following mESC differentiation caused by LIF withdrawal. Expression of 
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the activated mutant of β-catenin maintains the expression level of NANOG, as well 
as the long-term proliferation of ESCs, even in the absence of LIF. Furthermore, β-
catenin interacts with POU5F1 to up-regulate NANOG and interacts with NANOG 
with POU5F1 to assist in the LIF dependent self-renewal of ESCs. Sato et al. (2004) 
showed that addition of recombinant WNT3a to hESC under feeder-free conditions 
can stimulate proliferation; however it was later demonstrated that this does not 
suffice to maintain or expand undifferentiated status for longer periods of time 
(Dravid et al., 2005). Increasing β-catenin signaling by treatment with WNT3a-
conditioned medium or by over-expression of β-catenin promotes neural lineage 
commitment by hESCs (Otero et al., 2004). In a different study, Lako et al. (2001) 
showed that the over-expression of WNT3 up-regulates brachyury expression 
(mesodermal marker) and encourages differentiation towards the haematopoietic 






Figure 6: Canonical WNT pathway in ESC (Kikuchi et al., 2006). Binding of 
Wnt to its receptor, Frizzled and co-receptor LRP5/6 facilitates the liberation 
of β-catenin from its sequestration complex. The now stabilized β-catenin 
translocates to the nucleus where it binds to the promoter of its downstream 
target genes through interaction of Tcf and Lef. 
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PI3K (Phosphoinositide 3-kinases) 
PI3Ks are enzymes that phosphorylate phospholipids at the plasma membrane. On 
being activated, PI3K phosphorylates PtdIns(3,4)P2 and generates PtdIns(3,4,5)P3 
which is a target of PH domain (pleckstrin homology domain)-containing proteins 
and acts as a second messenger. Proteins such as AKT (also known as PKB) interact 
with PtdIns (3,4,5)P3 via PH domains and are subsequently translocated to the plasma 
membrane. Activation of AKT plays important roles in cell proliferation and survival 
through phosphorylating various substrates. PI3K and AKT proteins can be detected 
throughout murine pre-implantation development and inhibition of AKT activity 
results in significant delay in blastocysts hatching (Riley et al., 2005).  
 The PI3K pathway is activated by several growth factors and cytokines 
including insulin and LIF via tyrosine kinases. In addition to these exogenous factors, 
the PI3K pathway is endogenously activated by the constitutively active Ras family 
protein ERas (ESC-expressed Ras; Takahashi et al., 2005). The PI3K pathway utilizes 
multiple downstream effectors, including mTOR (mammalian target of rapamycin), 
which have shown to be essential for proliferation in mouse ESCs and early embryos 
(Takahashi et al., 2003; Murakami et al., 2004; Figure 7). Forced expression of a 
dominant-negative mutant (Paling et al., 2004) and treatment with a specific inhibitor 
of PI3K (LY294002; Paling et al., 2004; Armstrong et al., 2006) demonstrated that 
PI3K was important for maintenance of the undifferentiated state of mouse and 
human ESCs (Figure 7). It has also been shown that PI3K may promote self-renewal 
in both mouse and human ESCs by inhibiting the Ras/MAPK pathway, but precise 
mechanisms remain elusive (Li et al., 2007; Paling et al. 2006). Watanabe et al. 
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(2006) show that myristoylated, active form of Akt (myr-Akt) maintained the 
undifferentiated phenotypes in mouse ESCs without the addition of LIF (Figure 7). 
Moreover, the inhibition of PI3K activity with either pharmacological or genetic tools 
results in decreased transcription of NANOG and decreased NANOG protein levels 
(Storm et al., 2007). There is evidence that PI3K pathway is important for the self-
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Figure 7: Role of PI3K signaling in ESCs. Activation of PI3K activates the 
Ras/MAPK, AKT and mTOR signaling pathways which, are involved in 
the self-renewal and proliferation of ESCs. 
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SRC Family of Tyrosine Kinases 
 The SRC family of non-receptor protein tyrosine kinases regulates diverse 
processes such as cell division, motility, adhesion, differentiation, and survival. 
Anneran et al. (2004) showed that cYES, a member of the SRC family of non-
receptor tyrosine kinases, is highly expressed in mouse and human embryonic stem 
(ES) cells. The expression of kinase active mutants of Src and Hck can maintain 
ESCs in an undifferentiated state when LIF concentrations are reduced but not absent 
(Boulter et al., 1991; Ernst et al., 1996). cYes kinase activity is regulated by LIF and 
serum and is down-regulated when cells differentiate. Selective inhibition or knock-
down of SRC family kinases decreases growth and expression of pluripotency genes 
















Comparison of human and mouse embryonic stem cells 
 The derivation of murine ESCs was reported in 1981 (Martin; Evans and 
Kaufmann) followed almost 20 years later by derivation of human ESCs (Thomson et 
al., 1998).  Whereas mESCs have been instrumental in answering numerous questions 
related to mammalian developmental biology, hESCs are considered promising 
sources for therapeutic cell transplantation.  
ESCs have core key characteristics: 
 They have the ability to self-renew for extended periods of time.  
 They exhibit lack of contact inhibition.  
 They have a high nucleo-cytoplasmic ratio and a short G1 cell cycle phase.  
 ESCs can spontaneously differentiate and can be stimulated to differentiate in 
vitro into various cell types including germ cells.  
 In suspension they form embryo-like aggregates called ‘embryoid bodies’ 
comprising of derivatives of all the three germ layers.  
 On in vivo ectopic transplantation ESCs give rise to teratocarcinomas and 
when combined with normal pre-implantation embryos, these cells contribute 
to all tissues and organs including the germline. 
 Despite sharing key core characteristics, mouse and hESCs differ in 
morphology and growth properties. mESCs have a high alkaline phosphatase activity 
that can be measured by enzyme-based reactions or antibodies. mESCs grow in tight 
round colonies whereas hESCs generally grow in flat colonies with distinct borders. 
mES have a shorter doubling time (Burdon et al., 2002) as compared to hESCs (Amit 
et al., 2004). mESCs are more amenable to dissociation with enzymes such as trypsin, 
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a prerequisite for clonal proliferation; whereas hESCs are routinely cultured via 
mechanical passaging and are prone to differentiation on enzymatic dissociation into 
single cells. In serum-free culture conditions, mESCs require supplementation with 
LIF (Smith et al., 1988). In defined culture conditions, the addition of BMP4 
complements the actions of LIF (Ying et al., 2003). In contrast, LIF does not support 
pluripotency in hESCs.  Human ESCs are routinely grown in the presence of FGF2 
(Amit et al., 2000). Moreover, supplementing the culture medium with Activin A 
(Vallier et al., 2005) or the BMP4 inhibitor, Noggin (Wang et al, 2005) has shown to 
be beneficial in maintaining pluripotent hESCs. 
 Studies in both systems support the existence of a core molecular program of 
‘stemness’ that is conserved evolutionarily. There is a panel of surface markers and 
transcriptional factors shown to be expressed in ESCs that are used to classify them as 
pluripotent. However, mESCs and hESCs again show differences in the expression of 
some of these surface and molecular markers (Table 2), in the culture conditions and 
in their responsiveness to extrinsic signals. Some of these cell-surface markers are 
also detected in somatic cells that arise later in development, thus making them useful 
only as markers of undifferentiated cells in a specific temporal window when used 
with other ESC defining criteria (Koestenbauer et al., 2006). There are three 
commonly used forms of stage-specific embryonic antigens (SSEA): SSEA-1, SSEA-
3 and SSEA-4, which are expressed in different stages of development and patterns in 
mESCs and hESCs. SSEA-1 is a glycophingolipid with a lactoseries core; SSEA-3 
and 4 are also glycophingolipids but with a globoseries core (Draper and Andrews, 
2004). SSEA-1 is expressed on the surface of pre-implantation stage murine embryos 
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and is reported to play a role in cell-cell adhesion between blastomeres. SSEA-3 and 
4 are expressed in the ICM and on undifferentiated hESCs but not mESCs. Tumor 
rejection antigen (TRA-1-60, TRA-1-81) and germ cell tumor monoclonal-2 (GCTM-
2) are antibodies against antigens associated with pericellular matrix keratin 
sulfate/chondroitin sulfate proteoglycan and mark undifferentiated hESCs but not 
mESCs (Koestenbauer et al., 2006). In addition, CD9 antigen is expressed on both 
mES and hESCs whereas osteopontin is expressed only on hES and PECAM-1 
(CD31) and the Forssman antigen only on mESCs (Koestenbauer et al., 2006; Stern et 
al., 1978). 
 Both mESCs and hESCs are pluripotent cell populations derived from the pre-
implantation embryo: they exhibit the hallmarks of pluripotent cells, but differ in the 
signaling pathways that help maintain them and in the surface markers that 
characterize them. This leads to an important question as to which of these markers 
are optimal for characterizing putative ESC lines in other species and which extrinsic 
ligands ought to be included in the culture medium to provide optimal culture 
conditions. Despite the vast number of studies with mESC and hESCs, it is not known 
why the efficiency of ESC derivation is so species and strain dependant. Hence, it is 
more likely than not that, ES-like cells and ESCs derived from other species will 
display characteristics that they may share with both these cell types or are a unique 






   
Surface Markers hESC mESC 
 
SSEA 1 - + 
SSEA3/4 + - 
TRA-1-60 + - 
TRA-1-81 + - 
GCTM-2 + - 
Forssman antigen - + 
CD9 antigen + + 
Osteopontin + - 
PECAM-1 - + 




Overview of Objectives and Experimental Design 
 
Characterization of markers of pluripotency in bovine blastocysts 
 ESCs are pluripotent cells derived from the pre-implantation embryo that have 
been liberated from their fate of differentiation and are maintained in conditions that 
promote their proliferation in a pluripotent state. Pluripotent cells derived from 
bovine blastocysts should express the same markers of pluripotency as the population 
of pluripotent cells of the ICM of the blastocyst. Therefore, the markers of 
pluripotency normally used to characterize mouse and human ESCs were first 
evaluated for their expression in bovine blastocysts. Bovine blastocysts were 
analyzed by immunocytochemistry for the presence of NANOG, POU5F1, SSEA1 
and SSEA4. It was expected that the information obtained would indicate whether the 
expression patterns of the markers would resemble that of mESC, hESC or would 
share characteristics with both or neither. 
 The transcription factors NANOG, POU5F1 and SOX2 regulate pluripotency 
in the pre-implantation mouse and human embryos and ESCs derived from the ICM. 
The expression of these transcription factors is an indicator of their pluripotency. 
Hence, the derivation of a pluripotent cell population from the embryo is likely to be 
influenced by the presence of the above mentioned transcription factors in the 
embryo. The expression of NANOG and POU5F1 was measured among individual 
bovine blastocysts by quantitative RT-PCR. The expression level was normalized to 
the level of β-actin in the embryos. The results thus obtained would indicate whether 




Expression of genes related to pluripotency and differentiation in ICM explants 
 Most published reports of bovine ES-like cells assess the state of pluripotency 
in the colonies after a few passages. If the culture conditions are not optimal, the 
colonies will have already progressed towards a path of differentiation by this time 
point. There are no published reports of the status of the expression of the 
transcription factors NANOG, SOX2 and POU5F1 during the initial days of explant 
culture. This study evaluated whether the colonies derived from the ICM expressed 
these transcription factors in the initial days of culture and how long they could 
maintain expression when cultured in ESC medium not supplemented by any growth 
factors. At the same time markers of differentiation were also evaluated to assess any 
differentiation and if so which lineages the cells of the ICM explant would follow.  
 
Candidate gene expression in ICM explants 
 Growth factors can promote the proliferation and maintenance of pluripotent 
cells. In defined culture conditions, LIF supplementation supports mESC proliferation 
whereas FGF2 supports hESC proliferation. In order to identify which signaling 
pathways are expressed in the ICM explants, candidate transcripts representative of 
the various signaling pathways important for mESCs and hESCs were evaluated by 
semi-quantitative RT-PCR. The candidate genes belonged to the Jak-STAT (GP130, 
LIFR), WNT (β-CATENIN, FZLD), BMP4 (BMPR1A, BMPR2, ID1, ID3), FGF 
(FGFR1), and Activin (ALK4, ACTRIIB) pathways. To assess the effects of 
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passaging on gene expression, the same candidate genes were evaluated in ICM 
explant colonies in passages 0-2. 
 
Effect of cytokine supplementation 
 In defined culture conditions, the presence of cytokines and growth factors 
improves the survival of pluripotent cells.  Murine ESCs are routinely cultured in 
media supplemented with LIF. BMP4 also supports pluripotency of mESCs in 
defined culture conditions. In contrast, hESCs are cultured in media supplemented 
with FGF2, Activin A, or Noggin. In order to identify which cytokines might help 
maintain bovine pluripotent cells, ICM explants were cultured in media supplemented 
with cytokines (Noggin, BMP4, FGF2, Activin A or Noggin + FGF2; details on page 
48). Since there is sufficient published evidence that LIF does not affect the 
maintenance of pluripotency in bovine ES-like cells, we chose not to study its effect 
on ICM explants. The expression of the pluripotency-determining transcription 
factors (NANOG, POU5F1 and SOX2) was measured across passages 0-2 by 
quantitative RT-PCR. The expression level was normalized to β-actin for each 
sample. The concentration and the passage number served as the main effects, 
whereas the replicate served as the random effect. (For detailed methods, see page 
62).  
 
Selective ablation of differentiated cells 
 ESCs and ES-like cells can undergo spontaneous differentiation as is 
characteristic of pluripotent cells. The differentiating cells secrete ligands that 
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stimulate other pluripotent cells to follow specific differentiation lineages. The 
strategy of selective ablation was adopted in order to eliminate the differentiation-
inducing cells. To meet this end, a vector was constructed that had a hygromycin 
phosphotransferase gene under the control of the NANOG promoter. Transgenic 
pluripotent cells bearing this gene were expected to survive in the presence of 
hygromycin as long as the cells were pluripotent and the NANOG promoter was 
active. Cells that differentiate would succumb to the toxic effects of hygromycin, thus 
allowing pluripotent cells to proliferate. This experimental approach was predicted to 




Material and Methods 
ICM explant culture 
Preparation of feeder layer 
 Feeders for the culture of ICM-derived explants were made from STO MEFs 
(mouse embryonic fibroblasts; CRL-1503, ATCC, Manassas, VA). The MEFs were 
cultured in feeder medium (FM) composed of Knockout DMEM (Cat # 10829, 
Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine serum (FBS; Cat # 
SH 30070.03; Hyclone, Logan, UT) and 1% penicillin-streptomycin (10,000 IU each; 
Cat # 15140-122, Invitrogen). MEFs were mitotically inactivated (blocked) by 
incubating an 80% confluent layer of STO MEF in 0.01 mg mitomycin (Cat # 
M0503, Sigma-Aldrich, St. Louis, MO) per ml of FM for 2.5 hrs followed by 
extensive washing in Dulbecco’s phosphate buffered saline (DPBS; Cat # 14190-136, 
Invitrogen). Blocked cells were frozen as stocks of 4 x 106 cells per ml of 
cryoprotectant medium (FM supplemented with 10% FBS and 10% DMSO). For 
creation of feeder layers, blocked MEFs were plated at a density of 5 x 104 cells/ cm2. 
 
Isolation of ICM 
 Day 6 IVP bovine morulae were obtained from Bomed Inc. (Wisconsin). In 
vivo bovine morulae were obtained from the Wye Research and Education Center 
(University of Maryland, College Park) by flushing superovulated cows using 
standard techniques. These embryos were cultured overnight in G-2 version 3 embryo 
culture medium (Vitrolife, Englewood, CO) supplemented with 5% FBS (Cat # SH 
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30070.03E; Hyclone). Expanded blastocysts were transferred to a dish containing 
embryonic stem cell medium (ESCM) comprised of DMEM supplemented with 15% 
FBS, 1% glutamine (Cat # 35050-61; Invitrogen), 1% non-essential amino acids (Cat 
# 11140, Invitrogen), 1% penicillin-streptomycin (Cat # 15140-122; Invitrogen), and 
1% β-mercaptoethanol (Cat # 19470590, ICN Biomedicals Inc., Aurora, OH). The 
blastocysts were dissected manually under a stereoscope using a microdissection 
knife (ESE020, AB Technologies, Pullman, WA) and 27-gauge needle to isolate the 
ICM from the trophectoderm. 
 
Culture of ICM 
 Isolated ICMs were cultured in ESCM in groups of 2 to 5 on blocked feeders 
in 12-well tissue culture dishes. Freshly isolated ICMs attached to the feeders and 
formed outgrowths. The culture medium was changed every other day and the 
colonies were passaged every 6-7 days. The colonies were passaged by manually 
dissecting colonies into 0.1 mm pieces using 27 gauge needles. When required, pieces 
of colony were cryopreserved in cryoprotectant medium (ESCM supplemented with 
10% FBS and 10% DMSO). 
 For the cytokine experiments, ICMs were isolated, cultured and passaged as 
indicated above. The culture medium (ESCM) was supplemented with one of the 
following cytokines: rhBMP4 (0, 5, 10, or 15 ng/ml; Cat # 314-BP, R and D Systems, 
Minneapolis, MN), Noggin (0, 250, 500, or 750 ng/ml; Cat # 120-10, Peprotech, 
Rocky Hill, NJ), Activin A (0, 10, 25, 50 ng/ml; Cat # 338 AC, R and D systems) or 
FGF2 (0, 12, 40, or 100 ng/ml; Cat # 133-FB, R and D systems) or Noggin (500 
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ng/ml) + FGF2 (40 ng/ml). The selection of cytokines was based on their use in 
hESCs and mESCs and the results obtained from the candidate gene expression 
analysis of early ICM explants. The concentrations used were based on respective 
published recommendations for use in mESCs and hESCs. Each study was repeated 
twice on independent occasions except for Noggin supplementation which was 
repeated thrice. On each occasion, 3-7 ICM explants were analyzed at each 
concentration and at each passage. 
Sample Collection 
 For analysis of gene expression during the initial days of culture (days 0-12), 
2-4 colony ICM outgrowths were pooled in lysis buffer (Absolutely RNA Nanoprep 
Kit, Cat # 400753; Stratagene, La Jolla, CA) for RNA extraction and further analysis 
(pages 71 and 76). Day 0 samples represent freshly isolated ICM explants that have 
not been cultured. For analysis of candidate genes (page 80) and for analysis of effect 
of cytokine supplementation (page 86), individual colonies were sampled at the end 
of each passage. On each occasion, a small portion of the colony (0.1mm) was 
removed for further propagation prior to sample collection. Then the remainder of the 
colony was collected in lysis buffer for RNA extraction and further analysis.  
 Individual embryos (n=16) were collected in lysis buffer for RNA extraction 





Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
Semi-quantitative RT-PCR 
Sample treatment: Embryos, individual and pooled colonies were collected in 
lysis buffer. Total RNA was extracted from embryos and cell colonies using the 
Absolutely RNA Nanoprep Kit. The total RNA yield from pooled ICM explants was 
298.14+444.57 ug and it ranged from 10.2 ng-1570.5 ng. The total RNA yield from 
individual ICM explants in the cytokine study was 261.24+268.69 ug and it ranged 
from 23.9 ng-1527.3 ng. The RNA yield was lower for samples collected during 
Passage 0 and between Days 1- 6. Non-reverse-transcribed RNA was used as a 
control for genomic DNA contamination. Dnase treatment was conducted during the 
RNA extraction protocol to avoid contamination with genomic DNA. Total RNA was 
quantified using the Spectrophotometer (ND-1000, NanoDrop Technologies; 
Wilmington, DE) or was quantified at Center for Advanced Research in 
Biotechnology (CARB), University of Maryland. For each study, the amount of total 
RNA used for cDNA synthesis was adjusted such that similar amounts of RNA were 
being used for each sample in the study to enable semi-quantitative PCR analysis. 
First strand cDNAs were synthesized using Superscript III First-Strand Synthesis 
System for RT-PCR (Cat # 18080-051; Invitrogen). 
PCR primers were designed based on published nucleotide sequences when 
available or were based on sequence similarity between the mouse and human 
nucleotide sequences for the respective genes (Table). Primers were designed using 
the online software available at Sigma-Genosys 




(IDT; http://www.idtdna.com/analyzer/Applications/Oligo Analyzer). cDNAs were 
amplified with PfuUltra hotstart PCR master mix (Cat # 600250; Stratagene) or 
recombinant Taq DNA polymerase (Cat # 10342-053; Invitrogen) according to the 
manufacturer's instructions.  For each set of PCR reactions, a cDNA sample positive 
for the respective gene(s) and a cDNA sample negative for the respective gene(s) 
were included to confirm the specificity of reaction (Table 7). In addition, a reaction 
without cDNA was also included to test for contamination by genomic DNA.  
The PCR thermocycling conditions were the following: an initial denaturation 
step at 94°C for 3 min followed by 35 cycles (except ACTB where 20 cycles were 
run) of 94°C for 30 sec, primer specific annealing temperature for 30 sec, 72°C for 45 
sec extension, and a final extension at 72°C for 10 min. PCR products were separated 
by electrophoreses through a 1.5% Tris-acetate-EDTA agarose gel stained with 
GelStar (Cat # 50535; Cambrex Bio Science, Rockland, ME). Gels were imaged with 
Chemidoc XRS system (BioRad Inc., Hercules, CA). To retrieve amplified PCR 
products, DNA bands were excised from the gel and extracted with Qiaquick gel 
extraction kit (Cat # 28704; Qiagen, Valencia, CA). The extracted DNA was 
sequenced at the sequencing facility at University of Maryland (College Park, MD). 
 
Quantitative RT-PCR 
 Total RNAs were extracted, and first strand cDNAs were synthesized as 
indicated above. PCR primers were designed based on published nucleotide 
sequences when available or were based on sequence similarity between the mouse 
and human nucleotide sequences for the respective genes (Table 8). Primers were 
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designed using the online software available at Sigma-Genosys and Intergrated DNA 
Technologies.Gene transcripts were quantified by real-time PCR using the iCycler 
thermocycler (BioRad Inc.) and detected using SYBR Green fluorochrome (Cat # 
170-8882; IQ SYBR Green Supermix, BioRad Inc.). All reactions were run in 
duplicate or triplicate. In most of the studies, the difference in Ct values among 
replicates for each of the genes varied between 0-0.3. If the difference between these 
technical replicates exceeded 0.5, the data was not included in the analysis. Relative 
levels of expression were determined with the 2-ΔΔCt method, where ΔCt = Ct target gene 
- Ct internal reference, and ΔΔCt =ΔCt sample – ΔCt calibrator. β-actin served as the internal 
reference gene, and samples with no cDNA served as controls for the specificity of 
the reaction. A pool of cDNAs for each study served as the calibrator. The specificity 
and integrity of PCR products was confirmed through the melt-curve analysis. 
 
Single-cell nested PCR 
 Single transfected fibroblasts were placed in microcentrifuge tubes 
(containing a 5 µl solution of 400 ng/µl Proteinase K/17 µM SDS) using a fine pulled 
glass pipet. The tubes were incubated at 50°C for 1 h followed by denaturation at 
99°C for 30 min. 45 µl of PCR master mix containing 25 pmol external primers 
(specific for HP) was added and the product (451 bps) was amplified.  The external 
PCR product was used as a template for the next round of nested PCR using 10 pmol 
of each internal primer (specific for HP). PCR products (97 bps) were separated by 
electrophoreses through a 2% Tris-acetate-EDTA agarose gel stained with GelStar. 
Untransfected fibroblasts served as the negative control and plasmid DNA carrying 
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the hygromycin phosphophotransferase (HP) served as a positive control. A total of 
48 transfected fibroblasts maintained under G418 selection for more than 4 weeks 
were screened for the presence of the gene. All showed a positive band whereas the 




 Blocked STO MEFs served as a negative control whereas hTera-2 cells 
(human embryonal carcinoma, Cat # CRL-1973, ATCC) and mESC (R1, ATCC) 
served as positive controls for ICC. Blastocysts and ICM-derived colonies were fixed 
in 4% formaldehyde for 20 min and washed three times with TBST buffer (Tris 
buffered saline Tween-20; 20mM Tris-HCl, 0.15 M NaCl, and 0.05% Tween-20, pH 
7.4). Permeabilization was performed in a solution composed of 0.2% Triton X-100 
and 0.1% Tween-20 in distilled water for 10 min. Nonspecific reactions were blocked 
with 10% normal goat (SSEA-1, SSEA-4, POU5F1) or donkey (NANOG) serum 
(Sigma-Aldrich) for 30 min at room temperature. The samples were incubated 
overnight at 4oC with primary antibodies [(POU5F1, 1: 50 dilution; Cat # SC-9081, 
Santa Cruz Biotechnology), (SSEA-1, 1:50 dilution; Cat # SC-21704; Santa Cruz 
Biotechnology), (SSEA-4, 1:50 dilution; Cat # SC-21704 Santa Cruz Biotechnology), 
NANOG, 1:150 dilution; Cat # 500-P236, Peprotech)]. The samples were washed 
extensively with TBST buffer, and exposed to secondary antibody (1:200 dilution, 
AlexaFluor 448, Invitrogen) for 30 minutes at room temperature. The primary 
antibody was omitted for use as a negative control. These were then washed and 
stained with 1µg/ml Hoechst 33343 (Sigma-Aldrich) per ml DPBS for 10 minutes 
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and whole mounted onto slides using Antifade mounting solution (Cat # P-7481; 
Molecular Probes, Invitrogen). Images of the embryos and colonies were taken with a 
Leica DM IRE2 inverted microscope (Vashaw Scientific, Norcross, GA). 
Alkaline Phosphatase staining 
 The tissue culture dish containing the respective colonies was rinsed with PBS 
and fixed using 80% cold ethanol at 4°C overnight. The fixed cells were incubated 
with freshly made alkaline phosphatase (AP) solution. The AP solution was made 
from 0.5% diazonium salt of fast red (Sigma-Aldrich), 0.01% alpha-naphthyl 
phosphate (Sigma-Aldrich), 0.06% magnesium chloride (Sigma-Aldrich) and 0.45% 
borax in deionized water. The cells were exposed to the solution for 20 min, rinsed 
with PBS and scored immediately for the number of stained colonies. The positively 
stained colonies represented alkaline phosphatase activity. 
 
Vector construction 
 Bovine genomic DNA was extracted using DNeasy Tissue Kit (Qiagen) and 
446 base pairs (bps) of the NANOG promoter were cloned via PCR from the genomic 
DNA.  The Hygromycin phosphotransferase (HP) gene (1021 bps) was cloned from 
the pEF5/FRT/V5-DEST vector. The primers were designed to add sites specific for 
digestion by restriction endonucleases (RE) and overlap between the two genes 
(Figure 8, Table 3). After the PCR amplification, a Bam HI site was located 5’ to the 
NANOG promoter sequence; the HP gene carried a Kozak sequence and Sca I site 5’ 
and a Hind III site 3’ to it. Two products were designed: one with a stop codon after 
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the HP gene (NANOG promoter- HP; NH) and one without the stop codon after GFP 
(NANOG promoter- HP -GFP; NHG; Figure 8).  
 After amplifying the two DNA products individually (NANOG promoter and 
HP), both the products were pooled into the same tube and subjected to two rounds of 
PCR in the absence of primers to enable annealing of the products. This was followed 
by further rounds of PCR to amplify the fusion product of the two genes (site overlap 
extension, SOE). The fusion product was cloned into a vector using the pcDNA 
3.1/V5 His TOPO TA Expression Kit (Invitrogen). One Shot® TOP10 Chemically 
Competent Cells (E.Coli; Invitrogen) were transformed with the DNA according to 
the manufacturer’s recommendations. The transformed bacteria were plated on LB 
(Luria Bertani) agarose plates containing carbenecillin (100 µg/ml) and cultured 
overnight at 37ºC to select for the bacteria carrying the plasmid. Individual colonies 
were screened by PCR for the presence of the DNA insert and amplified in LB broth 
supplemented with carbenecillin (100 µg/ml). The plasmid carrying the insert was 
extracted and purified using the QIAprep Spin Miniprep Kit (Qiagen). 
 The NANOG promoter-HP gene product was cloned via PCR from the 
pcDNA 3.1 vector using forward primer specific to NANOG promoter and reverse 
primer specific to HP. The DNA and the target vector (pAcGFP; Clonetech, 
Mountain View, CA) were both individually digested overnight with Bam HI and 
Hind III REs (NEB, Opswich, MA) at 37ºC and purified using Purelink PCR 
Purification Kit (Invitrogen). 
 Both fusion products (NH and NHG) were individually ligated overnight with 
the target vector at 16ºC using T4 DNA ligase (NEB) and cloned into the multiple 
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cloning site of the pAcGFP1-1 vector. The ligated vector-DNA inserts were 
transformed into One Shot® TOP10 Chemically Competent Cells (E. Coli; 
Invitrogen). The transformed bacteria were plated on LB (Luria Bertani) agarose 
plates containing kanamycin (100 µg/ml) and cultured overnight at 37ºC to select for 
the bacteria carrying the plasmid. Individual colonies were screened by PCR for the 
presence of the DNA insert. Bacterial clones positive for the presence of DNA insert 
were cryopreserved in LB broth supplemented with 80% glycerol. The bacteria 
carrying the plasmid were amplified in LB broth supplemented with kanamycin (100 
µg/ml). The plasmid carrying the insert was extracted and purified using the PureLink 
HiPure Plasmid Maxiprep Kit (Invitrogen). 
 The plasmid was further tested by restriction mapping and was then 
sequenced at CBR, University of Maryland to ascertain the presence of the fusion 
























C T A G T GGATCCTTATTCCTTTGCCCTCGGA (stop codon) 
or 










Hygromycin phosphotransferase NANOG promoter 
Figure 8: Strategy for the Site Overlap Extension PCR 

































HindIII-NANOG promoter-ScaI-Kozak sequence-hygromycin phosphotransferase- BamHI 
Dark grey: NANOG promoter               Underlined: restriction endonuclease specific sites 
Light grey: hygromycin phosphotransferase  Italicized: Kozak sequence 




Culture and passage 
 R1 mESCs (ATCC) were cultured in ESCM supplemented with 1000 units/ 
ml leukemia inhibiting factor (LIF). These cells were cultured on gelatin-coated tissue 
culture plates at a density of approx 3.5 x 104 cells/ cm2. The media was changed each 
day and the cells were passaged every 2-3 days by enzymatically dispersing the 
colonies with 0.25% trypsin-EDTA (Invitrogen). 
 
Hygromycin sensitivity curve 
 Mouse ESCs were cultured on a 24 well tissue culture dish as mentioned 
above at a density of 2 x 104 cells/ well. Hygromycin was added to two wells each at 
concentrations of 0, 0.5, 2.5, 25, 50, 100, 200 µg/ml. The culture media was changed 
each day and cells were not passaged for 5 days. Colonies were stained for the 
presence of alkaline phosphatase (AP) and the numbers of colonies positive for AP 
were counted in each well. This experiment was replicated twice. 
Transfection and selection of cells for stable integration of the transgene 
Both plasmids (NH and NHG) were digested using restriction endonucleases (BglII 
and NotI), and the fragment containing the transgene was isolated by running on an 
agarose gel and purifying the excised gel fragment with the QIAquick Gel Extraction 
Kit (Qiagen).  
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 mESC were suspended at a density of 5 x 105 cells/ well in a gelatin coated 
(0.1%; Cat # G1393, Sigma-Aldrich) 24-well tissue culture dish, and 2 wells each 
were transfected with 0.8µg DNA each (cut as well as uncut plasmids) using a DNA: 
liposome ratio of 1:2 (Cat # 11668-027, Lipofectamine 2000, Invitrogen). 
Hygromycin (100 µg/ml; Cat # 10687-010, Invitrogen) was added to the wells 18 
hours after the transfection to select for cells carrying the transgene. Surviving cells 
were passaged and cultured in selection medium (ESCM supplemented with 
hygromycin) for 5 passages. Individual colonies (n= 24 each) were picked, and 
propagated as individual clones while being maintained under hygromycin selection. 
The clones were cryopreserved in ESCM cryoprotectant medium.  
 
Transfection and selection of bovine fibroblasts 
Culture and passage 
 Bovine fetal fibroblasts (obtained from USDA, courtesy of Ann Powell and 
Bob Wall) were cultured in Feeder Medium at a density of 5 x 104 cells/ cm2. The 
cells were passaged every 3-4 days enzymatically using 0.25% trypsin-EDTA. 
 
Geneticin and hygromycin sensitivity analysis 
 Bovine fibroblasts were cultured as mentioned above on a 24 well plate at a 
density of 5 x 104 cells/ cm2. Geneticin (Invitrogen) was added to 2 wells each at 
concentrations of 0, 50, 100, 200, 400, 600, 800, 1000 µg/ml, and media was changed 
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each day. Cells were not passaged for 5 days. The number of cells in each well was 
counted 6 days after initiation of geneticin supplementation. 
 Bovine ICM explants were cultured as described previously. Hygromycin was 
added to two wells each (each well containing 3 colonies) at concentrations of 0, 0.5, 
1.0, 2.5, 12.5, 25, 50, 100 and 200 µg/ml. The culture media was changed every other 
day and colonies were observed for surviving cells after 5 days. At the end of 5 days 
there were no surviving cells in the wells treated with 100 and 200 µg/ml hygromycin 
(Table 9, Appendix). 
Transfection and selection of stable integrated transgenic cells 
Bovine fibroblasts were suspended at a density of 2 x 106 cells/ cm2 on a gelatin 
coated 100 mm tissue culture dish and transfected with a 16 µg DNA using a DNA: 
liposome ratio of 1:2 (Lipofectamine 2000). The cells were selected for the presence 
of the transgene by adding Geneticin (Cat # 10131-035, Invitrogen) at a concentration 
of 400 µg/ml. Surviving cells were passaged and continued to be maintained in 
selection medium (feeder medium supplemented with 400 µg/ml geneticin) for 3 
weeks. These bovine fibroblasts were cultured at a low density (1 x 105 cells) in a 100 
mm tissue culture dish in selection medium. After 10-15 days of culturing the cells in 
selection medium, clonally growing colonies were harvested and propagated further. 
Hand-made cloning 
Cytoplast preparation 
 Bovine oocytes matured for 20 hrs (during shipping from Minitube Inc., Mt 
Horeb, WI) were stripped of cumulus cells using 1 mg hyaluronidase (Cat # H-3884, 
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Sigma-Aldrich) per ml in Emcare (Cat # CECFS, Immuno-Chemical Products, New 
Zealand). All embryo manipulation was performed in Emcare supplemented with 
20% FBS (T20). Zona pellucida was dissolved with 2 mg pronase (Cat # P8811, 
Sigma) per ml in T20. The oocytes were incubated for 10 min in cytochalasin B (2.5 
µg per ml T20; Sigma C-6762) and bisected in a tissue culture dish with a micro-
dissection knife (ESE020, AB Technologies) under a stereoscope. The halves were 
incubated in Hoechst solution (Cat # 14533, Bisbenzimide H33342; Fluka 
Biochemica, Buchs, Switzerland) to label the DNA at a concentration of 5 µg 
bisbenzimide per ml in Emcare for 10 min and screened under a fluorescent 




 Transfected bovine fibroblast clones were maintained at confluency for 4-5 
days under G418 selection in a 24 well dish. Fibroblasts from a single well were 
dispersed using trypsin into a single cell suspension in Emcare.  
 The cytoplast halves were washed through a dish of phytohemagglutinin 
(PHA, Sigma L-8754; 0.5 mg per ml Emcare) and a fibroblast cell was sandwiched 
between two cytoplast halves. Fusion medium consisted of 0.25 M sorbitol, 100 µM 
calcium acetate, 0.5 mM magnesium acetate, 0.1% fatty acid-free BSA (Sigma-
Aldrich) in distilled water. The cytoplast-fibroblast pair was equilibrated in fusion 
medium and placed between the wires of the fusion chamber (BTX Electroporator 
Electro Cell Manipulator ECM 2001, UK). The fusion machine was set according to 
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the following parameters: alternating current (AC) = 20 V, direct current (DC) = 168 
V (3.36 kV/cm), pulse duration = 16 ms, number of pulses = 1, and post-AC pulse = 
1s. AC/DC pulses were applied and the triplets were moved to droplets in G1 medium 
and cultured at 37°C, 5% CO2. During this time duration, the triplets fused to form a 
single rounded cell. 
 
Embryo culture 
 The cells were activated 3 hrs after fusion in a solution containing 5 µM 
calcium ionophore (Ionomycin, Sigma, Cat # I-0634). The reconstructed embryos 
were cultured for 3-4 hrs in 2 mM DMAP (dimethyl amino-purine; Sigma, Cat # 
D2692) at 39°C, 5% CO2. The embryos were thoroughly rinsed with Emcare and 
further cultured in embryo culture medium (G-1 version 3 supplemented with 10% 
FBS) in microwells in 30-µl microdroplet overlayed with oil at 39°C in 5% CO2, 5% 
O2, and 90% N2.  The embryos were scored 4 days after activation and blastomeres 
were selected for derivation of cell lines. Since these embryos lack a covering of zona 
pellucida, they cleaved to form an aggregate of blastomeres.  
 
Propagation of transgenic cells 
 The blastomeres were placed on a blocked feeder resistant to hygromycin 
(SCRC-1045; ATCC) and maintained in ESCM in the presence or absence of Noggin 
(500 ng/ml). A day after plating the blastomeres, the medium was supplemented with 




 Ct (Cycle threshold) values from quantitative real-time PCR were normalized 
to β-Actin.  In addition to β-Actin, the samples were also analyzed for GAPDH and 
the values were found consistent for both genes. Levels of mRNA reported are the 
means and SEs of the relative expression levels described.  
 Results for the ICM explant gene expression studies were analyzed as a One-
Way Analysis of Variance (ANOVA) using the PROC MIXED procedure of the 
SAS. The expression relative to ACTB was the dependent variable and the day of 
analysis was the independent variable. A pairwise comparison was conducted to 
compare the expression between two consecutive days using the PDIFF procedure 
(SAS). Differences were considered significant at P < 0.05. 
 Results for the cytokine studies were analyzed by ANOVA using the PROC 
MIXED procedure of the SAS. The expression relative to ACTB was the dependent 
variable. The concentration, passage number and the interaction of the passage and 
concentration served as fixed effects. The replicates or trial number served as the 
random effect. Where an interaction was found significant the main effects were 
omitted from the model. If no effect of the concentration was observed, the 
concentration variable was also omitted from the model. The changes in the model 
statements were made in order to maximize the degrees of freedom. A pairwise 
comparison was conducted to compare the expression at each passage and 
concentration to the respective control at that passage and concentration using the 





Markers of pluripotency in embryos 
 Day 7 bovine IVP blastocysts were individually collected, and mRNA 
transcript levels were quantified by RT-PCR. A total of 16 embryos were evaluated. 
However, the CT values were found to be consistent for 8 of the embryos for which 
the data has been presented. The pluripotency-related genes, NANOG and POU5F1 
were expressed in all the embryos tested. On further examination, the expression 
values as determined by quantitative RT-PCR were found to vary relative to the 
expression of β-actin in the individual embryos. The mean expression (mean + SEM) 
of the two genes among embryos was 6.28 + 13.62 for NANOG and 2.33 + 4.23 for 
POU5F1 (Figure 10). 
 IVP bovine blastocysts were examined for the expression of markers of 
pluripotency (Nanog, Pou5f1, SSEA1 and SSEA4) by subjecting the embryos (8-10 
total blastocysts per marker) to immunocytochemistry (ICC). The ICC was conducted 
on two separate pools of embryos on two different days. On each occasion 4-5 
embryos were tested per marker. Nanog expression in the ICM was localized to the 
nucleoplasm as well as the nucleoli, whereas it was restricted to the nucleoli of the 
trophectoderm cells (Figure 11 A-E). Pou5f1 was expressed in the nuclei of ICM as 
well as trophectoderm (Figure 11 F-J). SSEA 1 (Figure 11 K-O) was expressed in a 
punctuate manner the entire surface of the blastocyst (ICM as well as trophectoderm). 
However SSEA 4 (Figure 11 P-T) was not detected on the surface of any blastocyst 
tested. Ntera cells (human carcinoma cell line) and mESC served as positive controls 
for the sensitivity of the primary antibodies (nTera: Nanog, Pou5f1, SSEA4; mESC: 
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SSEA1). Embryos exposed to the respective secondary antibody without prior 
exposure to the respective primary antibodies served as negative controls for the 
specificity of secondary antibody. On each occasion, the nTera-2 cells and mESCs 
stained positive for the respective antibody whereas none of the negative controls 
exhibited any staining. 
 
 
Figure 10. Expression of the pluripotent genes, NANOG and POU5F1 in day 7 
IVP bovine blastocysts. 
Day 7 bovine blastocysts were individually collected and mRNA transcript levels 
for NANOG and POU5F1 were determined in each embryo via quantitative RT-
PCR. The CT values were normalized to β-actin which served as the internal 
reference. The data was analyzed by the 2-ΔΔCt method. The NANOG expression 
is represented by the white bars and the POU5F1 expression by black bars. 





































Figure 11. Expression of ESC markers in Day 7 bovine blastocysts. 
Bovine blastocysts were fixed and stained with the DNA specific stain H33342 
and with antibodies specific to markers of pluripotency. The images were taken 
with Leica immunofluoresence microscope, bar = 50 µm. 
 
Panel A-T represents the following labeling pattern:  
NANOG expression in blastocyst with FITC labeled secondary antibody against 
primary antibody (green) (A); nuclei labeled with H33342 (red) (B); merge of A 
and B (C); blastocyst labeled with secondary antibody without exposure to 
primary antibody and overlaid with H33342 staining (D); nTera-2 with FITC 
labeled secondary antibody without exposure to primary antibody (E) 
POU5F1 expression in blastocyst with FITC labeled secondary antibody against 
primary antibody (green) (F); nuclei labeled with H33342 (blue) (G); blastocyst 
labeled with secondary antibody without exposure to primary antibody (I); nTera-
2 with FITC labeled secondary antibody without exposure to primary antibody (J) 
SSEA 1 expression in blastocyst with FITC labeled secondary antibody against 
primary antibody (green1) (K); nuclei labeled with H33342 (red) (L) merge of K 
and L (M); blastocyst labeled with secondary antibody without exposure to 
primary antibody and overlaid with H33342 staining (N); mESC with FITC 
labeled secondary antibody without exposure to primary antibody (O) 
SSEA 4 expression in blastocyst with FITC labeled secondary antibody against 
primary antibody (green) (P); nuclei labeled with H33342 (red) (Q); merge of P 
and Q (R), blastocyst labeled with secondary antibody without exposure to 
primary antibody and overlaid with H33342 staining (S); nTera-2 with FITC 
















































Pluripotency and differentiation related gene expression in ICM explants 
 ICM explants derived from IVP blastocysts were cultured on blocked feeders 
and the resulting colonies were evaluated on days 0 through 12 for the relative 
levels of mRNA expression of the pluripotent genes, NANOG, POU5F1 and 
SOX2. Day 0 samples represent isolated ICM explants that have not been 
cultured. This experiment was conducted on two independent sets of embryos. On 
each day of sample collection 2-4 colonies were pooled for analysis. The 
expression relative to ACTB was the dependent variable and the day of analysis 
was the independent variable. A pairwise comparison was conducted to compare 
the expression between two consecutive days using the PDIFF procedure (SAS). 
Differences were considered significant at P < 0.05. Day 0 samples represent 
freshly isolated ICM explants that have not been cultured. The three pluripotency-
determining transcription factors, NANOG, POU5F1 and SOX2 were expressed 
in the ICM explant in the initial days of culture but their expression reduced 
significantly with continued culture. The expression of NANOG decreased 
significantly on day 4 of culture and then on day 7 after which it remained low 
(P< 0.01; Figure 12A). The expression of POU5F1 decreased significantly on day 
3 of culture and remained low till day 10 and then increased (P<0.01; Figure 
12B). The relative expression of POU5F1 seemed to increase after day 10 but 
there was variability between the two independent replicates. The expression of 
SOX2 decreased significantly on day 7 of culture after which it remained low 






 The above colonies were also evaluated for the relative levels of mRNA 
transcripts representative of the three lineages, neuroectoderm (NCAM), 
mesoderm (BMP4) and endoderm (HNF4), as well as the trophectoderm marker 
(CDX2). CDX2 (Figure 13A) NCAM (Figure 13B), BMP4 (Figure 13C), and 
HNF4 (Figure 13D) were present on all days of culture. This data suggests that on 
continued culture the explant cells lose their pluripotent character and 
differentiate into all three lineages as well as trophectoderm. In addition, the 
presence of CDX2 in the ICM explants may indicate the presence of 
trophectoderm cells remaining during the isolation of the ICM. The variability in 
the expression level of the differentiation related genes from day to day of the 
culture may be attributed to the fact that the sample collected on each day 
represents an individual ICM explant and that the particular sample may vary in 
differentiated character as compared to other explants.  
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Figure 12.  Expression of pluripotency-related genes in cultures of ICM explants 
derived from in vitro produced blastocysts on Day 0 through Day 12 (D0=isolated 
ICMs, D1-12=cultured ICM explants). 
Relative levels of mRNA expression were determined for the pluripotent genes, 
NANOG (Panel A), POU5F1 (Panel B) and SOX2 (Panel C). All CT values were 
normalized to β-actin which served as the internal reference. The panels on the 
left represent the mean of the expression of the genes relative to ACTB for both 
the experiments. The standard error bars represent the variation between the two 
independent experiments. The panels on the right represent the expression of the 
genes relative to ACTB in the two individual experiments. The standard error bars 
represent the variation between the technical replicates for each experiment. Each 
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Figure 13.  Expression of differentiation-related genes in cultures of ICM explants 
derived from in vitro produced blastocysts Day 0 through Day 12 (D0=isolated 
ICMs, D1-12=cultured ICM explants). 
Relative levels of mRNA expression were determined for the differentiation 
related genes, CDX2 (trophectoderm marker; Panel A), NCAM (neuroectoderm 
marker; Panel B), BMP4 (mesoderm marker; Panel C) and HNF4 (endoderm 
marker; Panel D). All CT values were normalized to β-actin which served as the 
internal reference. The panels on the left represent the mean of the expression of 
the genes relative to ACTB for both the experiments. The standard error bars 
represent the variation between the two independent experiments. The panels on 
the right represent the expression of the genes relative to ACTB in the two 
individual experiments. The standard error bars represent the variation between 
the technical replicates for each experiment. Each experiment was conducted on a 
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 In order to assess whether NANOG, POU5F1 and SOX2 were expressed in 
ICM explants isolated from in vivo derived bovine blastocysts, ICM isolated from in 
vivo derived blastocysts were cultured on blocked feeders and the resulting colonies 
were evaluated on days 2, 4 and 6 for the relative levels of mRNA expression of the 
pluripotency-determining transcription factors, NANOG, POU5F1 and SOX2. Day 0 
samples represent isolated ICM explants that have not been cultured. This study was 
conducted on 2 individual sets of embryos. On each occasion, 2-4 ICM explant 
colonies were pooled and collected for analysis on each day of sample collection. The 
samples were analyzed for relative levels of mRNA of the above mentioned 
transcription factors and markers of differentiation. All the three transcription factors 
NANOG (Figure 14A), POU5F1 (Figure 14 B) and SOX2 (Figure 14C) were 
expressed in the ICM explants for the limited duration the cultures were evaluated.  
 The same ICM explants were also analyzed for the relative levels of mRNA 
expression of the markers of the three lineages, neuroectoderm (NCAM), mesoderm 
(BMP4) and endoderm (HNF4) as well as the trophectoderm marker (CDX2). CDX2 
(Figure 15A), NCAM (Figure 15B) and BMP4 (Figure 15C) were present on all days 
of culture and the level of expression increased with the continued culture. HNF4 
(Figure 15D) was not present at the start of culture but began to be expressed with 
continued culture. This data suggests that the explant cells differentiate into all three 
lineages as well as trophectoderm. In addition, the presence of CDX2 in the ICM 
explants may indicate the presence of trophectoderm cells remaining during the 
isolation of the ICM. 
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Figure 14.  Expression of pluripotency-related genes in cultures of ICM explants 
derived from in vivo derived blastocysts Day 0 through Day 12 (D0=isolated 
ICMs, D1-12=cultured ICM explants). 
Relative levels of mRNA expression were determined for the pluripotent genes, 
NANOG (Panel A), POU5F1 (Panel B) and SOX2 (Panel C). All CT values were 
normalized to β-actin which served as the internal reference. The panels on the 
left represent the mean of the expression of the genes relative to ACTB for both 
the experiments. The standard error bars represent the variation between the two 
independent experiments. The panels on the right represent the expression of the 
genes relative to ACTB in the two individual experiments. The standard error bars 
represent the variation between the technical replicates for each experiment. Each 
experiment was conducted on a pool of 2-4 ICM explants. 
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Figure 15.  Expression of differentiation-related genes in cultures of ICM explants 
derived from in vivo derived blastocysts Day 0 through Day 12 (D0=isolated 
ICMs, D1-12=cultured ICM explants). 
Relative levels of mRNA expression were determined via quantitative RT-PCR 
for the differentiation related genes, CDX2 (trophectoderm marker; Panel A), 
NCAM (neuroectoderm marker; Panel B), BMP4 (mesoderm marker; Panel C) 
and HNF4 (endoderm marker; Panel D). All CT values were normalized to β-
actin which served as the internal reference. The panels on the left represent the 
mean of the expression of the genes relative to ACTB for both the experiments. 
The standard error bars represent the variation between the two independent 
experiments. The panels on the right represent the expression of the genes relative 
to ACTB in the two individual experiments. The standard error bars represent the 
variation between the technical replicates for each experiment. Each experiment 
was conducted on a pool of 2-4 ICM explants. 
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 The ICM explants were further evaluated by semi-quantitative RT-PCR for 
the same panel of candidate pathway genes as previously described. The genes 
belonging to the Jak-STAT (GP130, LIFR), BMP4 (BMPR1A, BMPR2, ID1, ID3), 
WNT (FZLD, CATENIN), FGF2 (FGFR1) and ACTIVIN (ALK4, ACTR2B) 
pathways were present on all days of culture, 0-12 (Figure 16). These genes were 
analyzed for both sets of ICM explant cultures and Figure 16 is a representative of the 
semi-quantitative RT-PCR data for both the sets.  
 RNA samples from the ICM explants were further evaluated by semi-
quantitative RT-PCR for the expression of candidate genes belonging to the different 
signaling pathways responsible for pluripotency in mESC and hESC. The genes 
belonging to the Jak-STAT (GP130, LIFR), BMP4 (BMPR1A, BMPR2, ID1, ID3), 
WNT (FZLD, CATENIN), FGF2 (FGFR1) and Activin (ALK4, ACTR2B) pathways 
were present on all days of culture 0-6 (Figure 17). The above experiment was 
conducted on two independent sets of embryos. On each day of sample collection 2-3 
colonies were pooled for analysis. 
 In a follow up experiment, ICM explants derived from IVP blastocysts were 
passaged every 6-7 days and individual colonies evaluated at the end of each passage 
(0-2) for the expression of the same panel of candidate genes via semi-quantitative 
RT-PCR. The efficiency of colony formation from ICMs (Figure 19 B) isolated from 
day 7 blastocysts (Figure 19 A) was 60%. The ICM explant colonies grew from 0.1 
mm to an average size of 3x3-4x4 mm in a span of 6 days (Figure 19 C). This 
experiment was conducted on two separate occasions on two independent sets of ICM 
explants. In both occasions, 4 ICM explant colonies were followed from passage 0 
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through passage 2.The genes representative of the pathways were present through all 
the three passages. However, NANOG was not detected in any of the samples, SOX2 
was present in samples of passage 0 and POU5F1 was present in all samples passage 
0-2 (Figure 18). 
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Figure 16.  Expression of candidate genes in cultures of ICM explants derived from in 
vitro produced blastocysts grown on feeders on day 0 through day 12 (D0-D12). 
 
Expression levels of candidate genes belonging to the different signaling pathways 
responsible for pluripotency in mESC and hESC were determined via semi-
quantitative RT-PCR. Each band represents a pool of 2-4 ICM explants. cDNA from 
representative cells and tissues served as positive and negative controls for the 
respective genes (Table 5).  
 





















Figure 17.  Expression of candidate genes in cultures of ICM explants derived from in 
vivo derived blastocysts grown on feeders on days 0 through days 6. 
 
Expression levels of candidate genes belonging to the different signaling pathways 
responsible for pluripotency in mESC and hESC were determined via semi-
quantitative RT-PCR. Each band represents a pool of 2-4 ICM explants. cDNA from 
representative cells and tissues served as positive and negative controls for the 



























Figure 18.  Expression of candidate genes in cultures of ICM explants derived 
from in vitro produced blastocysts grown on feeders across passages 0-2. 
In the following panel, 1-4 represent individual colonies/primary cultures that 
were analyzed across passages 0-2. Expression levels of candidate genes 
belonging to the different signaling pathways responsible for pluripotency in 
mESC and hESC were determined via semi-quantitative RT-PCR. This 
experiment was conducted on two individual sets of ICM explants and each 
explant was monitored starting passage 0 through 2. The following panel is a 
representative of one of the sets of cultures. Each band represents an individual 
ICM explants.  
 



















Figure 19. Representative pictures. 
Panel A. Day 7 bovine blastocyst 
Panel B. Dissected ICMs. 















Effect of cytokine supplementation on pluripotent gene expression in ICM explants 
 IVP blastocyst derived ICM explants were cultured in the presence of 
selective cytokines. Samples were collected from the cultures at the end of each 
passage (0-2). A portion of the ICM explant was used for futher propagation at the 
end of each passage. Each ICM explant was processed and analyzed individually. The 
effect of supplementation of each cytokine ( Noggin, BMP4, FGF2, Activin A and 
Noggin + FGF2) on the expression of pluripotency related transcription factors 
(NANOG, POU5F1, SOX2) was determined by quantitatively measuring the 
transcripts by qRT-PCR. The data was analyzed as a One- way ANOVA with 
concentration of the respective cytokine and the passage number as fixed effects and 
the trial or replicate number as a random effect. The expression relative to ACTB was 
the dependent variable. An interaction of the concentration and passage number was 
also assessed as a part of the model statement. Significance was determined at 
α=0.05. 
 ICM derived explants cultured in ESCM supplemented with 250, 500 or 750 
ng/ml Noggin exhibited a significant increase in the expression of NANOG when 
compared to control (0ng/ml). The experiment was conducted on three different sets 
of ICM explants on three independent occasions, twice using in IVP blastocysts and 
once using in vivo produced embryos. This effect of Noggin was independent of the 
concentration of Noggin used, however, it was affected by the passage number with 
the relative change in expression being significant at Passage 0 (P<0.01) and Passage 
1 (P<0.05) but not at Passage 2 (P<0.1). At the same time there was an interaction 
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between the passage number and Noggin supplementation. However there was no 
effect on the expression of POU5F1 or SOX2 (Figure 20).  
 There was no significant effect of supplementation of either BMP4 (5, 10 or 
15 ng/ml; Figure 21), FGF2 (12, 40 or 100 ng/ml; Figure 22), Activin A (10, 25, 50 
ng/ml; Figure 23) or a combination of Noggin (500 ng/ml) and FGF2 (40 ng/ml) 
(Figure 24). Each of these experiments were repeated on two independent sets of 
embryos on two separate occasions. Although there was no significant effect of the 
supplementation of the above mentioned cytokines, POU5F1 and SOX2 expression 
was more susceptible to the passaging and their expression decreased drastically in all 
studies. Athough the NANOG expression did not increase significantly with 
respective to the control in the Noggin+FGF2 study, there was variability between the 
expression levels of the treated samples but not in the controls. This suggests that 
individual colonies were reacting differently to the cytokines. However, an ICM 
explant that expressed high NANOG in any one passage did not necessarily show a 
high NANOG in any other passage. At the same time it did not correlate with high 
expression of POU5F1 or SOX2. 
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Figure 20. Effect of supplementation of different concentration of Noggin (0, 250, 
500 or 750 ng/ml) on expression of genes related to pluripotency in ICM explants 
across passages 0-2. 
Individual ICM explants were evaluated for NANOG, POU5F1 and SOX2 at the 
end of each passage by quantitative RT-PCR. The standard error bars represent 
the variation among individual samples. The numbers above each bar represents 
the total number of ICMs evaluated at each concentration and each passage. β-
actin served as the internal reference gene. Athough the effect of Noggin on 
NANOG was independent of the concentration of Noggin used, it was affected by 
the passage number with the relative change in expression being significantly 
different from the respective controls at Passage 0 (*; P<0.01) and Passage 1 (**; 
P<0.05) but not at Passage 2 (***; P<0.1). 
 
 































































































































Figure 21. Effect of supplementation of different concentration of BMP4 (with 0, 
5, 10 or 15 ng/ml) on expression of genes related to pluripotency in ICM explants 
across passages 0-2. 
Individual ICM explants cultured in ESCM supplemented BMP4 were evaluated 
for the expression of NANOG, POU5F1 and SOX2 relative to ACTB by 
quantitative RT-PCR. The numbers above each bar represents the total number of 
ICMs evaluated at each concentration and each passage.The standard error bars 
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Figure 22. Effect of supplementation of different concentration of FGF2 (0, 12, 40 
or 100 ng/ml) on expression of genes related to pluripotency in ICM explants 
across passages 0-2. 
 Individual ICM explants cultured in ESCM supplemented FGF2 were evaluated 
for the expression of NANOG, POU5F1 and SOX2 relative to ACTB by 
quantitative RT-PCR. The numbers above each bar represents the total number of 
ICMs evaluated at each concentration and each passage.The standard error bars 
represent the variation among individual samples. 






















































































































Figure 23. Effect of supplementation of different concentration of Activin A (0, 
10, 25 or 50 ng/ml) on expression of genes related to pluripotency in ICM 
explants across passages 0-2. 
Individual ICM explants cultured in ESCM supplemented Activin A were 
evaluated for the expression of NANOG, POU5F1 and SOX2 relative to ACTB 
by quantitative RT-PCR. The numbers above each bar represents the total number 
of ICMs evaluated at each concentration and each passage.The standard error bars 
represent the variation among individual samples. 
 




















































































































Figure 24. Effect of supplementation of Noggin (500 ng/ml) and FGF2 (40 ng/ml) 
on expression of genes related to pluripotency in ICM explants across passages 0-
2. 
Individual ICM explants cultured in ESCM supplemented Noggin + FGF2 were 
evaluated for the expression of NANOG, POU5F1 and SOX2 relative to ACTB 
by quantitative RT-PCR. The numbers above each bar represents the total number 
of ICMs evaluated at each concentration and each passage.The standard error bars 
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Effect of Noggin (500 ng/ml) and FGF2 (40 ng/ml) on NANOG 


























Effect of Noggin (500 ng/ml) and FGF2 (40 ng/ml) on SOX2 expression 









































Generation of embryos following Hand-made Cloning 
 
 The presence of diffentiatiated cells in a population of pluripotent cells can 
induce the pluripotent cells to differentiate. It was hypothesized that by selectively 
ablating the diffentiating cells would assist to preserve the existing population of 
pluripotent cells and allow them to proliferate. To serve this end, a DNA construct, 
pNANhygro, was designed in which the hygromycin phosphotransferase gene was 
driven by the NANOG promoter. On transfection into cells, the construct would 
selectively confer hygromycin resistance to pluripotent cells and ESC progenitors. It 
has previously been shown that these 446 bases of the NANOG promoter include the 
regions important for the transcription of NANOG gene in mESCs (Wu and Zhen, 
2005). Previous experiments using the GFP reporter have shown the promoter to be 
active in mESCs. 
 The effectiveness of the promoter to direct the transcription of the hygromycin 
phosphotransferase was assessed by creating stably transfecting a R1 mESC line and 
culturing individual clones for extended periods of time in the presence of 
hygromycin (0.1 mg/ml). These clones were resistant to the presence of hygromycin 
and upon differentiation following the removal of LIF from the culture media the 
cells exhibited cell death (Table 12, appendix).  
 Once the effectiveness of the vector construct was established, it was 
transfected into bovine fetal fibroblasts. The fibroblasts were maintained in the 
presence of G418 over 3 weeks and clones were isolated. However, the clones 
seneseced when expanded futher in culture. The incorporation of the transgene in the 
fibroblasts was confirmed by performing a nested PCR on the single cells. The 
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fibroblasts were then used a donor cells for the somatic cell nuclear transfer 
procedure.  
 The procedure of Hand-made Cloning (HMC) is a variant of the Somatic Cell 
Nuclear Cloning (SCNT) procedure. This procedure was attempted on six 
independent occasions using different sets of oocytes (n=300). Bovine fibroblasts  
stably transfected with the DNA construct carrying the NANOG promoter-
hygromycin phosphotransferase were used as donor cells for cloning. Prior to HMC, 
the fibroblasts were maintained at confluency for 5 days to induce them to a quiescent 
state (G0 stage). After screening for absence of DNA, membrane integrity and 
cytoplast quality, cytoplast halves were selected for fusion with the donor cells (Table 
4, 5). Following fusion of the donor cell with the oocyte cytoplasts, 44 + 7.8 of the 
reconstructed oocytes exhibited healthy, rounded configurations (Table 5) and were 
activated with calcium ionophore. Control oocytes with intact zona pellucida (31.6 + 
14.4) and without zona pellucida (21.6 + 2.5) as well as cytoplasts containing DNA 
were activated as well (Table 5). Following activation, for each experiment, an 
average of 22.3 + 8.2 oocytes with intact zona pellucida, 15.5 + 2.42 oocytes without 
zona pellucida and 18.5 + 13.2 reconstructed oocytes cleaved to generate blastomeres 
(Table 5).  
 The blastomeres were transferred to hygromycin resistant blocked feeders 
four days after the activation of the reconstructed oocytes and cultured in ESCM. 
Hygromycin (0.1 mg/ml) was added to the medium the day after plating the 
blastomeres. Since pluripotent blastomeres of the pre-implantation embryo and 
progenitors of ES-like cells potentially have the NANOG promoter active, all cells in 
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which the gene is silenced following differentiation would be susceptible to the toxic 
effects of the antibiotic. In experiments 1-3, the ESCM was not supplemented with 
any cytokines (Table 6). The colony formation efficiency of this set of experiments 
(Expt 1-3) was 8.7%. The blastomeres initiated colonies by Day 2 but the colonies 
failed to survive any further.  In expts 4-6, the ESCM was supplemented with Noggin 
(500 ng/ml). The blastomeres formed colonies which survived and proliferated upto 
Day 6 when they were passaged (Table 6). The colony formation efficiency of this set 
of experiments (Expt 4-6) was 11.36%. The average size of the colony by Day 2 was 
1 x 1 mm and the average size by Day 6 was 4 x 4 mm. Blastomeres derived from 
pronase treated oocytes, oocytes with intact zona pellucida and cytoplast halves 
containing the DNA served as controls. The control blastomeres from all three groups 




Table 4: Flowchart indicating the procedure of Handmade Cloning (HMC) 
 
 Oocyte matured for 19-21 hrs 
Removal of cumulus 
Removal of zona pellucida Control oocyte for activation 
Control oocyte for activation 
Incubation in Cytochalasin B 
Bisection of oocytes 
Cytoplast half without DNA 
Coat cytoplast with PHA 
Stick PHA coated cytoplast half to a fibroblast 
Equilibrate cytoplast-fibroblast pair and a second 
cytoplast half in equilibration medium 
Fuse the above pair with a second cytoplast half 
Culture reconstructed oocyte in embryo culture medium 
Activate using calcium ionophore 
Culture in DMAP for 3.5 hrs 
Culture in embryo culture medium for 4 days 
Cytoplast half with DNA 
Stably transfected 
fibroblast in G0 
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Table 5. Generation of embryos following Hand-made Cloning. 
HMC was performed on six independent occasions using separate sets of oocytes 
(n=300).  Oocytes with or without the zona pellucida and cytoplast halves containing 
the DNA served as controls for the activation process. The reconstructed embryos 
cleaved to form blastomeres which were then cultured on feeders in the absence (Expt 
1-3) or presence (Expt 4-6) of Noggin (500ng/ml).  
 
Number of embryos cleaved 
Expt 
number 






































1 36  20 (55.55%) 25 25 
20 
(80%) 20 (80%) 5 (25%) 
2 43  20 (45.5%) 25 25 
15 
(60%) 18 (72%) 0 (0%) 
3 36  25 (69.4%) 20 20 
15 
(75%) 16 (80%) 18 (72%) 




(60%) 29 (69%) 




(70%) 30 (81%) 
6 46 39 (84.7%) 20 20 
14 
(70%) 15 (75%) 29 (74.3%) 








Table 6. Colony formation by blastomeres generated via HMC. 
Blastomeres formed by HMC were plated on feeders 4 days after activation. The 
blastomeres were cultured in ESCM in the presence of hygromycin (0.1mg/ml). The 
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Figure 25: Representative picture of a day 4 colony derived from embryos 








 Since the isolation of ESCs from mouse embryos more than two decades ago, 
researchers have been attempting to isolate ESC from various model organisms and 
domestic species such as the cattle. However, with the exception of the mouse ESCs 
no other species have exhibited clonal self-renewal and germline transmission. There 
have been reports of production of germline chimeras from ES-like cells in chicken 
(Pain et al., 1994; Mc Lavoir et al., 2006) and zebrafish (Ma et al., 2001) however 
these chimeras were generated using primary cultures and not from true cell lines. 
Even in mESC, most cell lines existing today have been derived from strain 129 and 
its sub-strains, and most other strains have proven to be refractory to the derivation of 
ESC (McWhir et al., 1999). Despite the many peer-reviewed journal articles 
describing ungulate ES or ES-like cell lines over the past 15 years, no proven 
ungulate ES cell lines currently exist. Most attempts at isolating ESCs and ES-like 
cells from cattle have been from the epiblast of the IVP embryos at the blastocyst 
stage (Cibelli et al., 1998; Mitalipova et al., 2001; Wang et al., 2005). It is unclear 
whether this lack of success is due to inferior starting material (poor quality 
embryos), the isolation procedure, the culture conditions or the refractoriness of the 
species (Keefer et al., 2007). At the same time, oocytes obtained from the 
slaughterhouse are isolated from ovaries at various stages of the estrus cycle. This has 
been shown to cause a variation in the developmental competence and gene 
expression profile of the resulting IVP embryos (Longeran et al., 2003, Niemann et 
al., 2000; Machatkova et al., 1996). However, studies using in vivo bovine embryos 
have not had better success at establishing ES-like cells. Real-time RT-PCR analysis 
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on individual embryos suggested a high variability in the levels of NANOG and 
POU5F1 of individual IVP blastocysts. Various published studies have indicated that 
IVP embryos exhibit a variation in the expression of genes regulating various aspects 
of embryonic growth and development (Lopes et al., 2007; Camargo et al., 2005). 
The variability in expression of the pluripotent transcription factors may compound 
the efficiency of derivation of ES-like cells using IVP embryos.  
 POU5F1 and NANOG, along with a series of cell surface markers (SSEA1, 
SSEA4, TRA-1-60, TRA1-81) have been used to characterize mouse and human 
ESCs. Although the expression patterns of ESC surface markers vary between 
humans and mice, nonetheless, these markers have proven useful in the 
characterization of ES cell lines (Henderson et al. 2002). For instance, SSEA1 is 
expressed in mESCs, whereas SSEA3 and SSEA4 are expressed in hESCs (Draper et 
al. 2002). One of the major problems encountered in monitoring the ES-like cells 
derived from bovine embryos has been the lack of data on the appropriate markers 
that can be used to characterize these cells.  In this study we found that SSEA1 but 
not SSEA4 was expressed on the surface of the bovine blastocyst in a punctate 
pattern. There have been mixed reports regarding the expression of SSEAs in bovine 
embryos and embryo derived cultures. Mitalipova et al. (2001) reported bovine ES-
like cells being positive for the expression of both antigens; Saito et al. (2003) 
reported these cells positive for SSEA1, whereas Wang et al. (2005) reported IVP 
blastocysts and ES-like cells derived from them to be SSEA4 positive. The reason 
behind these contradictory reports is not clear; however the difference in culture 
systems in different laboratories might be a contributing factor. Furthermore, unlike 
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the distinct localization of these surface markers to the ICM in mouse and human 
ESCs, SSEA1 in bovine was localized over both the ICM and trophectoderm in our 
study and therefore is not a definitive marker for bovine ES-like cells. 
 Immunolocalized Nanog protein was observed in the nucleoplasm and 
nucleoli of the bovine ICM cells but it was restricted to the nucleoli in the 
trophectoderm cells. This pattern is similar to that reported for caprine blastocysts 
(He et al., 2006), which is in contrast to that observed in the mice where Nanog 
expression is restricted to the ICM only (Hatano et al., 2005). He et al. (2006) 
confirmed the nucleolar localization of Nanog in the trophectoderm by double 
staining with anti-nucleolin and suggested this phenomenon to be a means of 
sequestration of Nanog in the trophectoderm. Pou5f1 was nuclear localized in the 
cells of the ICM as well as the trophectoderm. This pattern is in concordance with 
previously published reports in caprine, bovine and porcine blastocysts (He et al., 
2006; Kirchoff et al., 2000; van Eijk et al., 1999). In mouse (Kirchhof et al. 2000; 
Palmieri et al. 1994), monkey (Mitalipov et al. 2003), and human (Hansis et al. 2004) 
blastocysts, Pou5f1 expression is restricted to the ICM and is considered a major 
repressor of the trophoblast lineage. It has been suggested that POU5F1 expression in 
the trophectoderm of goat, bovine and porcine may be related to the longer period of 
trophectoderm proliferation before implantation in these domestic animals (Degrelle 
et al. 2005; Kirchhof et al. 2000). Hence, while Pou5f1 alone cannot serve as a 
definitive marker of ES-like cells in bovine by itself, it should be a part of the panel 
of pluripotency markers for characterizing bovine ES-like cells. 
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 In pre-implantation mouse embryos, the pluripotency determining 
transcription factors, POU5F1, NANOG and SOX2 are expressed in the ICM and 
epiblast of the blastocyst (Avilon et al., 2003; Palmieri et al., 1994). They are also 
highly expressed in human and mouse ESCs, and their expression diminishes when 
these cells differentiate and lose pluripotency (Ginis et al., 2004). The transcripts of 
NANOG and POU5F1 are routinely used as molecular markers in identifying the 
pluripotent colonies of mouse and human ESCs. However, few of the previously 
reported bovine ES-like cell lines were demonstrated to be POU5F1 positive 
(Mitalipova et al., 2001; Stice et al., 1996; Cibelli et al., 1998; Saito et al., 2003) 
except for one report by Wang et al. (2005) where they found NT derived ES-like cell 
lines positive for POU5F1. However, no such results were reported for IVP bovine 
embryos in that study. There is no published report for presence of NANOG in 
cultured ES-like cells in any domestic species reported thus far. 
 One of the aims of this research was to evaluate by RT-PCR if the 
pluripotency markers, NANOG, POU5F1 and SOX2 are expressed in early ICM 
derived explants. Our hypothesis is that the early loss of pluripotency-determining 
transcription factors in culture contributes to the difficulty in self-renewal of 
pluripotent cells derived from the embryos of domestic species such as cattle. Our 
results indicated that on culturing ICM cells derived from bovine blastocysts, 
NANOG, POU5F1 and SOX2 are expressed in the initial days of culture; however, 
with continued culture their expression diminishes. It is well known that for the 
maintenance of pluripotency, the relative levels of these three transcription factors 
needs to be optimum and any change in their ratio can initiate differentiation. At the 
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same time, markers of differentiation of all the three lineages as well as for the 
trophectoderm were present on all days of the culture in ICM explants. The presence 
of the trophectoderm marker, CDX2 suggests that remnants of the trophectoderm may 
have remained following the dissection. On the other hand it may also indicate the 
differentiation of ICM explant cells to a trophectoderm lineage. The presence of all 
the three lineages, endoderm (HNF4), mesoderm (BMP4) and neuroectoderm 
(NCAM) are also indicators of the spontaneous differentiation of the pluripotent cells 
of the ICM during culture. This is in accordance with the inherent nature of ESCs and 
ES-like cells to spontaneous differentiate into various lineages in culture, especially 
when the culture conditions are not optimal for the maintenance of pluripotency.  
 During routine derivation of mESCs and hESCs from blastocysts, it takes 6-7 
days from the attachment of ICM or the blastocyst before the cells are ready to be 
passaged for the first time. It is at that moment that pluripotent cells are 
morphologically identified and usually picked manually and sub-cultured. These cells 
are propagated to generate a population of pluripotent cells. Our results showed that 
on passaging the bovine ICM explants, NANOG and SOX2 are not expressed beyond 
the initial passage (P0); however, POU5F1 is expressed through passage 2. This study 
has for the first time shown that bovine ICM derived explants express the same 
molecular markers of pluripotency (NANOG, POU5F1 and SOX2) as mouse and 
human ESCs, albeit for a short duration. This result indicates that there may be a 
small window of time during which the cells are pluripotent allowing the possibility 
that appropriate manipulations may prolong the duration of expression of these 
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transcription factors. The data also suggest that the ICM explants undergo 
spontaneous differentiation into all three lineages early in culture. 
 In addition to the pluripotency-determining transcription factors, there are 
several signaling pathways that have been implicated in the maintenance of 
pluripotency in mouse, as well as, human ESCs. However ESCs from these two 
species vary in terms of which pathways are pertinent for the maintenance of 
pluripotency. Members of the following signaling pathways are highly expressed in 
pluripotent mESCs: Jak-STAT (Matsuda et al., 1999; Niwa et al., 1998) and TGF-β 
families (Ogawa et al., 2007); whereas the members of the following signaling 
pathways are highly expressed in pluripotent hESCs: FGF (Amit et al., 2000) and 
TGF-β families (Xu et al., 2005; Wang et al., 2005; Vallier et al., 2005; James et al. 
2005). On analyzing bovine ICM explants, transcripts for receptors belonging to the 
Jak-STAT pathway (LIFR and GP130); TGF-β pathway, BMP4 (BMPR1A, BMPR2) 
and Activin A (ALK4, ActRIIB);  WNT (FZLD); and FGF2 (FGFR) were present in 
cultures on Days 1-12 and they continued to be expressed on passaging as well.  
These results suggest that receptors belonging to the respective signaling pathways 
are actively transcribed. If these pathways are relevant for maintenance of 
pluripotency in bovine ICM explants, then the pathway may be stimulated by the 
application of appropriate ligands to act on downstream targets. 
 The loss of expression of pluripotent markers in the cultures of ICM explants 
in the initial days of culture is indicative of the fact that the culture environment is not 
optimal for the maintenance of pluripotency.  Mouse and human ESCs are known to 
spontaneously differentiate in culture, especially if the culture medium is not optimal 
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for the maintenance of pluirpotency. In order to provide the appropriate environment 
for culturing ESCs and ES-like cells, growth factors or cytokines are added to the 
hESC and mESCs culture medium. In mESC, the Jak-STAT pathway stimulated by 
LIF is most vital, and mESCs differentiate quickly when LIF is withdrawn from the 
culture medium (Smith et al., 1988; Niwa et al. 2001). Under defined conditions, 
supplementation with ligands of the TGF-β superfamily such as BMP4 (Smad 1/5/8 
mediated responses; Ying et al., 2003; Qi et al., 2004) or Activin A and Nodal (Smad 
2/3 mediated responses; Ogawa et al., 2007) increases the number of pluripotent 
mESC colonies. On the contrary, in hESCs application of Noggin inhibits the Smad 
1/5/8 mediated signaling by suppressing the BMP4 pathway. This increases the 
proportion of pluripotent human ESCs in culture (Wang et al., 2005). Additionally, 
supplementation with Activin A or Nodal alone or in combination with FGF2 
supports the maintenance of hESC in defined medium (Vallier et al., 2005; Beattie et 
al., James et al., 2005). LIF, however, is not effective in maintaining hESCs in 
culture. 
 We hypothesized that in order to extend the duration for which the expression 
of NANOG, POU5F1 and SOX2 can be maintained in culture, supplementation with 
cytokines and growth factors is necessary. Therefore, the culture media was 
supplemented with components of the TGF-β (BMP4, Noggin, Activin A) and FGF 
(FGF2) pathways. The choice of the factors and the concentration at which they were 
used was based on their pluripotency-supporting role in mESCs and hESCs (BMP4, 
Noggin, FGF2, Activin A and Noggin+FGF2). BMP4, Activin A or FGF2 did not 
affect the upregulation of any of the three transcription factors. Supplementation of 
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the culture medium with Noggin up-regulated the maintenance of NANOG mRNA in 
ICM derived explants across passages when compared to control cultures. The results 
from the supplementation of Noggin in the culture medium of ICM explants suggests 
that the regulation of pluripotency in bovine ICM explants may be more similar to 
hESCs than to mESCs. However, it did not effectively maintain the expression of 
POU5F1 or SOX2. As Noggin had a positive effect on NANOG expression, it was 
surprising to see the down regulation of POU5F1 and SOX2, since it is well known 
that these three transcription factors are tightly regulated and influence each other’s 
expression as well. Studies in hESCs have shown a beneficial effect of using FGF2 in 
combination with Noggin (Wang et al., 2005; Xu et al., 2005). It was anticipated that 
the combination of Noggin and FGF2 would help maintain the expression of 
pluripotency better than Noggin alone. Although the combination of Noggin+FGF2 
did not increase the expression of NANOG expression significantly, there was high 
variability in the expression of the transcription factors in the ICM explants cultured 
in the presence of the cytokines; this variability was not seen in the controls. This 
indicates that individual colonies may be responding differently to the 
supplementation. In the light of this observation it may be speculated that repeating 
the study with larger numbers or with embryos of a consistent quality may divulge the 
true effect of these cytokines. 
  Numerous attempts have been made to isolate ESCs from bovine embryos, but 
more often than not the primary colonies undergo spontaneous differentiation. Results 
from the culture of bovine ICM explants also showed a mixed population of cell types 
very early on in the culture. In mESC derivation, it is critical that the primary explant 
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be cultured for a sufficient time to allow multiplication of ESC progenitors yet 
without allowing extensive differentiation (Abbondanzo et al., 1993). The 
differentiation signals sent out by the differentiating cells in cultures of mESCs and 
hESCs can cause the pluripotent cells to differentiate as well. It is well known that the 
higher the percentage of pluripotent cells in a population, the greater is the chance of 
survival and propagation of the ESCs. In order to circumvent this problem the 
strategy of selectively ablating differentiating cells was adopted. This strategy has 
previously been implemented for derivation of ESCs from refractory strains of mice 
such as CBA (Gallagher et al., 2003; Mc Whir et al., 1996). Among mouse strains, 
genetic background strongly affects the efficiency of ESC isolation, and almost all 
ESC lines used for research are derived from strain 129 (Evans and Martin, 1981; 
Magin et al., 1992) and some from strain C57BL/6 (Kawase et al., 1994). McWhir et 
al. (1996) utilized a Neomycin cassette driven by the POU5F1 promoter to isolate 
pluripotent cells. Using this strategy they were able to generate germline pups from 
CBA ESCs. Prior to the above mentioned study it had not been possible to derive 
ESCs from the CBA strain, let alone generate germline chimeras. In the current study, 
the NANOG promoter was chosen instead of the POU5F1, because the expression of 
the latter is increased on differentiation into primitive endoderm and mesoderm cells 
as well (Niwa et al., 2000). Moreover, in bovine embryos the expression of POU5F1 
is not restricted to the pluripotent cells of the ICM but is expressed in the 
trophectoderm as well (van Eijk et al., 1999). Furthermore, NANOG not only inhibits 
the differentiation of stem cells into endoderm but also actively maintains 
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pluripotency, in contrast to the role of POU5F1 as a blocker of differentiation of  ICM 
and ESC into trophectoderm (Cavaleri and Scholer, 2003; Niwa et al., 2000).   
 Transgenic embryos were generated via Hand-made cloning that carried the 
hygromycin phosphotransferase gene under the control of the bovine NANOG 
promoter. It was hypothesized that since pluripotent blastomeres of the pre-
implantation embryo and progenitors of ES-like cells potentially have the NANOG 
promoter active, all cells in which the gene is silenced following differentiation 
would be susceptible to the toxic effects of the antibiotic. This would encourage the 
survival of pluripotent cells. It has previously been shown that these 446 bases of the 
NANOG promoter include the regions important for the transcription of NANOG 
gene in mice (Wu and Zhen, 2005). Previous experiments using the GFP reporter 
have shown the bovine NANOG promoter to be active in mESCs. On transfecting the 
construct into mESCs, the cells survived in the presence of hygromycin in culture 
thereby proving the efficacy of the vector construct to confer resistance to 
hygromycin. Loss of resistance to hygromycin following LIF removal confirmed the 
specificity of the NANOG promoter. Bovine fetal fibroblasts stably transfected with 
the pNANhygro vector construct were used as donor cells for creating embryos. 
These transgenic blastomeres formed colonies when grown on feeder cells and were 
able to proliferate when the medium was supplemented with Noggin. However, they 
failed to grow on passaging indicating that the culture conditions were not optimal for 
the NANOG promoter to remain active over extended culture.  
 Recently published research by Chambers et al. (2007) suggests that mESCs 
can maintain most of their pluripotent characteristics in the absence of NANOG. 
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Moreover, cells not expressing NANOG can generate NANOG expressing colonies 
and vice versa. In the light of these findings, it is probable that the expression of 
NANOG or the activity its promoter may not be a prerequisite for the maintenance of 
ES-like cells. This also raises questions regarding our strategy of selective ablation. 
The colonies generated by the HMC blastomeres succumbed to the effects of 
hygromycin when passaged. It is likely that our initial colonies were pluripotent but 
the NANOG promoter was silenced at passaging. This suggests that adoption of a 
different selection strategy or the removal of hygromycin at passaging may have 
permitted the survival and proliferation of pluripotent cells. However, other reports 
studying the over-expression of NANOG in ESCs have demonstrated it to be 
important for the maintenance of pluripotency and its utility as a marker of 
pluripotency (Darr et al., 2006; Hatano et al., 2005; Hyslop et al., 2005). Furthermore 
in order to truly define the role played by NANOG, further investigations are needed. 
 In summary, this research has shown that  
 Bovine blastocysts express NANOG and POU5F1. 
 ICM explant cultures express the established molecular markers of 
pluripotency (NANOG, POU5F1, and SOX2) during term culture, and  
 ICM explants express components of pathways known to be involved in 
maintenance of mouse and human ESCs. 
 Culture of ICM explants in Noggin helps maintain the expression of NANOG. 
 Selective ablation of differentiating cells in ICM explants can potentially 
facilitate survival and proliferation of pluripotent cells under optimized 





 The findings of this research showed that the transcripts for the pluripotency 
determining transcription factors, NANOG, POU5F1 and SOX2 are expressed in the 
ICM explants in the initial days of the culture. However, they disappear early in 
culture and at the same time there is a prominent presence of the markers of 
differentiation of all the three lineages as well of the trophectoderm. This indicates 
that though the cells are pluripotent for a while, there is spontaneous differentiation as 
the culture system is not optimal for sustenance of pluripotency. We were successful 
in improving the culture condition by supplementing the culture medium with the 
growth factor Noggin, which aided in maintaining the expression of NANOG. 
However, the culture conditions remained sub-optimal for the maintenance of the 
other two transcription factors (POU5F1 and SOX2). In the future, identification of a 
combination of cytokines might be able to improve the expression of all three 
transcription factors. 
 Most of the research in this study was conducted with embryos derived from 
slaughter house oocytes. The embryos thus obtained are highly variable in their 
quality and gene expression patterns. The possibility cannot be ruled out that using a 
more consistent source of such as embryos or embryos from similar genetic 
background might have helped alleviated the variation in the responses to the 
cytokine treatments. At the same time performing the experiments with a larger 
number of embryos might assist in mitigating the variation and other cytokines than 
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that were investigated in this research might prove to be effective in supporting the 
expression of the pluripotency-determining transcription factors.  
 The candidate gene expression demonstrated that the transcripts for 
representatives of the various signaling pathways were expressed in the ICM 
explants. It is important to pursue this further and investigate which pathways are 
actually functional by evaluating for the presence of activated secondary messengers 
of the pathways such as the Smad 1/5/8 in the BMP4 pathway, Smad 2/3 in the 
Activin pathway. Once it is established that the members of the respective pathways 
are not merely transcribed, but are actually functional steps can be taken to activate 
the concerned signaling pathway. This knowledge might be helpful in optimizing the 
culture conditions as well. 
 Several experiments that can be attempted to follow up this line of research 
demand a source of self-renewing cells. One approach to serve this purpose would be 
to over-express the NANOG gene in early ICM explants or create bovine embryos 
over-expressing NANOG for the purpose of deriving cells lines from them. The 
colonies thus obtained could then provide for a source of cells that could be utilized 
for performing experiments that require a large number of cells such as for examining 
the presence of signaling pathways and performing experiments like protein analysis 
by Western blots.  
 A similar approach that could be adopted would be to use bovine fetal 
fibroblasts for the purpose of reviving their pluripotent nature by introducing a set of 
transcription factors that have been proven to turn differentiated cells into pluripotent 
cells. This technique has been demonstrated by Yamanaka’s group (Okita et al., 2007; 
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Takahashi et al., 2006) where they generated cell lines resembling pluripotent stem 
cells by the retroviral introduction of Pou5f1, Sox2, c-Myc and Klf4. A similar study 
conducted in human somatic cells by Thomson’s group (Yu et al., 2007) using a 
similar set of transcription factors (Pou5f1, Sox2, c-Myc and Lin28) showed that this 
procedure is applicable in other species as well. Cells obtained by implementing this 
procedure in bovine cells should provide sufficient material for conducting further 
research. 
 The present research involved inserting of the NANOG promoter-hygromycin 
phosphotransferase construct into bovine oocytes via Hand–made cloning. The vector 
construct has been demonstrated to be functional in pluripotent cells of other species 
as well (pilot study done with mESCs). The same could be attempted with other 
species as well. The derivation of ESCs is governed by a strong genetic component. It 
is difficult to speculate which species would be more amenable to the procedure of 
selective ablation for the self-renewal of pluripotent cells. We already have frozen 
stocks of in vivo derived caprine blastocysts and also early passages (P0 and P1) of 
colonies derived from these blastocysts and this research could be replicated using 
them. 
 This study has been successful in identifying the key core transcription factors 
in bovine ICM explants. It has been shown for the first time that NANOG, POU5F1 
and SOX2 are expressed in cultures derived from the bovine embryos and that this 
expression is maintained in basal ESC medium, albeit for only a short time. We 
successfully identified a potential ligand (Noggin) that enables the maintenance of 
NANOG and might be the key to maintenance of pluripotency in bovine ES-like 
 114 
 
cells. Noggin blocks the BMP4 pathway from being activated by binding to its 
receptors. Further exploration of this pathway and the role activated Smad 1/5/8 and 
their target genes play in the regulation of pluripotency in bovine ICM explants and 
ES-like cells is likely to unravel the nature of these cells further. 
 Embryos generated via Hand-made cloning generated colonies in the presence 
of Noggin. It is likely that these colonies would have survived for longer periods of 
time if the culture system or passaging could be optimized. Once optimal conditions 
for maintenance of pluripotency are established, the culture system should allow the 
NANOG promoter to remain functional and the pluripotency maintaining factors 
would continue to be expressed.    
 The current research demonstrated that the molecular markers of pluripotency 
(NANOG, POU5F1, and SOX2) are expressed in bovine ICM explant cultures and 
can potentially be used for monitoring ES-like cells derived from bovine embryos.  At 
the same time candidate genes representing the signaling pathways implicated in 
maintenance of pluripotency are also expressed in ICM explant cultures and these 
pathways can potentially be stimulated to sustain pluripotency. We were also able to 
identify a potential ligand (Noggin) that might be critical in self-renewal of bovine 
ES-like cells. The tools for selective ablation of differentiating cells developed as part 
of this research also provide a means for creating an environment supportive of 
pluripotency. We are hopeful that future experiments built on the findings of this 





Bovine RT-PCR primers 
Table 7: List of bovine RT-PCR primers along with the product length, melting 
temperatures and the tissues that are positive and negative for the expression of the 
respective genes. 
 








LIFR fwd ATCATCAGTGTGGTGGCAAA 573 67.9 trophectoderm heart 
  rev CGCAAGACCAGGTGGTAACT   60.1     
GP130 fwd AGAAGCAGAGAATGCCCTTG 298  63.4 adipose pancreas 
  rev TCACTCCAGTCACTCCAGTA   58.3     
BMPR1A fwd AGCCTCCAGACTCACAGCAT 387 64 lung lymph node 
  rev ACCCAGAGCTTGACTGGAGA   64     
BMPR2 fwd CTGGACAGCAGGACTTCACA 381 64.2 lung muscle 
  rev CTTGGGCCCTATGTGTCACT   63.9     
ID1 fwd CTCCAGCACGTCATCGACTA 486 64.1 adipose lymph node 
  rev CTGAGAAGCACCAAACGTGA   64.1     
ID3 fwd ACTCACTCCCCAGCATGAAG 242 64.3 kidney lymph node 
  rev GTAGTCGATGACGCGCTGTA   64     
FZLD fwd CATTTGGTCAGTGCTGTGCT 632 64 heart uterus 
  rev CCATGAGCTTCTCCAGCTTC   64     
B-CATENIN fwd GCTTGGTTCACCAATGGATT 500 63.6 muscle uterus 
  rev TGATGTCTTCCCTGTCACCA   64.3     
ALK4 fwd TGACATGGAACGCATCTGGCAGTA 478 60 brain pancreas 
  rev AAGGGTGTACTGCACCTTCTCAGT   60     
ACTR2B fwd TCATGAACGACTTCGTGGCTGTCA 380 60 brain pancreas 
  rev AGCAGTGAGGTCACTCTTCAGCAA   60     
FGFR1 fwd ACACCTGCATCGTGGGAGAATGAGT 532 60 lung spleen 
  rev TCTTCTTGGTGCCGCTCTTCATCT   60     
ACTB fwd CTCTTCCAGCCTTCCTTCCT 513 63.6 heart   
  rev CACCTTCACCGTTCCAGTTT   63.8     
NANOG fwd  CAGTCCTGATTCTTCCACAA 696 60.25 blastocyst muscle 
  rev  TTACAAATCTTCAGGCTGTATGTT   61.8     
POU5F1 fwd GGTTCTCTTTGGAAAGGTGTTC  498 62.6 blastocyst muscle 
  rev ACACTCGGACCACGTCTTTC   64     
SOX2 fwd CAAAACCATCTCCGTGGTCT 300 63.8 brain kidney 
  rev ACATGTATTCTCGGCAGACT   63.6     
CDX2 fwd GACTACGGCGGATACCATGT 599 63.6 trophectoderm heart 
  rev CTGCGGTTCTGAAACCAAAT   63.8     
NCAM fwd CCGGCATTTACAAGTGTGT 595  61 kidney lymph node 




Bovine qRT-PCR primers 
Table 8: List of bovine quantitative RT-PCR primers along with the product length 
and the melting temperatures. 
 




ACTB fwd TTGCTGACAGGATGCAGAAG 142 60.14 
  rev TGATCCACATCTGCTGGAAG   60 
         
NANOG fwd GTCCCGGTCAAGAAACAAAA 107 63.7 
  rev TGCATTTGCTGGAGACTGAG   64.2 
         
POU5F1 fwd TGCAGCAAATTAGCCACATC 123 63.7 
  rev AATCCTCACGTTGGGAGTTG   63.8 
         
SOX2 fwd ACAGTTGCAAACGTGCAAAG 114 63.8 
  rev AGACCACGGAGATGGTTTTG   63.8 
         
GATA6 fwd ATACTTCCCCCACCACACAA 118 64 
  rev AGCCCGTCTTGACCTGAGTA   63.7 
         
CDX2 fwd CTCCTGGACAAGGACGTGAG 119 60 
  rev ACATGGTATCCGCCGTAGTC   60 
         
HNF4 fwd GGAGGATCCGGAATGAAAAAAGAAGCTGT 200 62.9 
  rev GAAGAATTCACAGACATCACCAAT   64.1 
         
NCAM fwd ACAAAGGCCGAGATGTCATCCTGA 108 60.2 
  rev AGCGGTAAGTGCCCTCATCTGTTT   60.6 
         
BMP4 fwd TCAGTGATGTGGGCTGGAATGACT 120 60.2 




Hygromycin sensitivity in bovine ICM explants 
Table 9: Senstivity of the bovine ICM explants to various concentration of 
hygromycin. Three ICM explants were plated in each well of a 12-well tissue culture 
dish. Wells (in duplicate) were supplemented with various concentrations of 
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Summary of total number of oocytes used and the respective colony formation 
efficiencies for each study 
 
Table 10: Total number of oocytes used in each study and the respective colony 
formation efficiencies for each study 
 
Study Number of blastocysts processed 
Colony formation 
efficiency (%) 
Gene expression in in vivo ICM 
explants (page ) 16 100 
Gene expression in in vitro ICM 
explants (page ) 64 90 
Gene expression in in vitro ICM 
explants after passaging (page ) 40 60 
Noggin study (page ) 60 73 
BMP4 study (page ) 40 65 
FGF2 study (page) 40 67 
Activin A study (page) 40 62 




Summary of total number of ICM explants evaluated for the expression of 
pluripotency determining transcription factors for each of the cytokine studies 
 
Table 11: Total number of ICM explants evaluated for the expression of pluripotency 
determining transcription factors in each of the cytokine studies 
 
Noggin 
Passage/conc 0 ng/ml 250 ng/ml 500 ng/ml 750 ng/ml 
P0 11 10 11 12 
P1 10 10 9 11 
P2 8 10 9 9 
 
BMP4 
Passage/conc 0 ng/ml 5 ng/ml 10 ng/ml 15 ng/ml 
P0 7 7 6 6 
P1 6 5 6 6 
P2 6 5 6 6 
 
Activin A 
Passage/conc 0 ng/ml 10 ng/ml 25 ng/ml 50 ng/ml 
P0 8 7 6 6 
P1 8 6 6 6 
P2 8 6 6 6 
 
FGF2 
Passage/conc 0 ng/ml 12 ng/ml 40 ng/ml 100 ng/ml 
P0 6 5 7 7 
P1 6 5 7 7 
P2 6 5 5 6 
 
 
Noggin (500 ng/ml)+FGF2 (40 ng/ml) 
Passage/conc Control Treatment 
P0 10 20 
P1 10 19 






Hygromycin resistance in stably transfected mESC clones 
 
Table 12: mESCs were plated in a 24-well plate at a density of 25,000 cells/well. The 
cells were cultured in ESCM supplemented with hygromycin (0.1 mg/ml) in the 
presence or absence of LIF. The resulting colonies were stained for alkaline 
phosphatase activity 5 days after plating the cells and the number of positive colonies 
was counted. 
 
 Number of AP 
positive colonies 5 
days in ESCM + 
LIF + hygromycin 
Number of AP 
positive colonies 5 
days in ESCM - 
LIF + hygromycin 
Well 1 676 0 
Well 2 712 0 
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